GeneDx (WGS) 10-Q 9 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 02, 2023
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-39482
Entity Registrant Name	GeneDx Holdings Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1966622
Entity Address, Address Line One	333 Ludlow Street
Entity Address, Address Line Two	North Tower
Entity Address, City or Town	Stamford
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06902
City Area Code	800
Local Phone Number	298-6470
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		25,590,133
Entity Central Index Key	0001818331
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Class A common stock
Entity Listings [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	WGS
Security Exchange Name	NASDAQ
Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share
Entity Listings [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share
Trading Symbol	WGSWW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 201,895	$ 123,933
Restricted cash	12,144	13,470
Accounts receivable, net	32,911	42,634
Due from related parties	636	708
Inventory, net	12,334	13,665
Prepaid expenses and other current assets	12,428	18,212
Total current assets	272,348	212,622
Operating lease right-of-use assets	33,235	32,758
Property and equipment, net	49,508	51,527
Intangible assets, net	183,144	186,650
Long-term restricted cash	900	900
Other assets	6,160	6,485
Total assets	545,295	490,942
Current liabilities:
Accounts payable and accrued expenses	69,889	84,878
Due to related parties	4,315	3,593
Short-term lease liabilities	5,199	6,121
Other current liabilities	39,629	49,705
Total current liabilities	119,032	144,297
Long-term debt, net of current portion	6,250	6,250
Long-term lease liabilities	63,883	60,013
Other liabilities	22,111	22,000
Deferred taxes	2,510	2,659
Warrant liability	440	418
Earn-out contingent liability	2,600	1,600
Total liabilities	216,826	237,237
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock, $0.0001 par value: 1,000,000 and 1,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	0	0
Class A common stock, $0.0001 par value: 1,000,000,000 and 1,000,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively; 24,193,436 and 11,773,065 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	2	1
Additional paid-in capital	1,513,877	1,378,125
Accumulated deficit	(1,185,410)	(1,124,421)
Total stockholders’ equity	328,469	253,705
Total liabilities and stockholders’ equity	$ 545,295	$ 490,942

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	24,193,436	11,773,065
Common stock, outstanding (in shares)	24,193,436	11,773,065

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenue	$ 43,139	$ 53,941
Cost of services (including related party expenses of $815 and $1,056 for the three months ended March 31, 2023 and 2022, respectively)	27,903	48,316
Gross profit	15,236	5,625
Research and development	14,592	21,315
Selling and marketing	13,452	25,629
General and administrative	43,689	46,702
Related party expenses	1,747	1,284
Impairment loss	2,120	0
Loss from operations	(60,364)	(89,305)
Other income (expense), net:
Change in fair market value of warrant and earn-out contingent liabilities	(3,453)	13,190
Interest income	732	27
Interest expense	(767)	(808)
Other income, net	2,716	0
Total other (expense) income, net	(772)	12,409
Loss before income taxes	(61,136)	(76,896)
Income tax benefit	147	0
Net loss and comprehensive loss	(60,989)	(76,896)
Net loss and comprehensive loss	$ (60,989)	$ (76,896)
Weighted average shares outstanding, Class A common stock (in shares)	20,061,945	7,405,113
Weighted average shares outstanding, Class A common stock (in shares)	20,061,945	7,405,113
Basic net loss per share, Class A common stock (in dollars per share)	$ (3.04)	$ (10.38)
Diluted net loss per share, Class A common stock (in dollars per share)	$ (3.04)	$ (10.38)
Class A Common Stock
Other income (expense), net:
Weighted average shares outstanding, Class A common stock (in shares)	20,061,945	7,405,114
Weighted average shares outstanding, Class A common stock (in shares)	20,061,945	7,405,114
Basic net loss per share, Class A common stock (in dollars per share)	$ (3.04)	$ (10.38)
Diluted net loss per share, Class A common stock (in dollars per share)	$ (3.04)	$ (10.38)
Diagnostic test revenue
Total revenue	$ 41,850	$ 52,495
Other revenue
Total revenue	$ 1,289	$ 1,446

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenue	$ 43,139	$ 53,941
Cost of services	27,903	48,316
Affiliated Entities
Cost of services	815	1,056
Diagnostic test revenue
Total revenue	41,850	52,495
Diagnostic test revenue | Affiliated Entities
Total revenue	842	170
Other revenue
Total revenue	1,289	1,446
Other revenue | Affiliated Entities
Total revenue	$ 0	$ 74

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Preferred Stock	Additional paid-in capital	Accumulated deficit	Class A Common Stock	Class A Common Stock Common Stock
Beginning balance, preferred stock (in shares) at Dec. 31, 2021		0
Beginning balance at Dec. 31, 2021	$ 388,103	$ 0	$ 963,543	$ (575,441)		$ 1
Beginning balance, common stock (in shares) at Dec. 31, 2021						7,352,958
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(76,896)
Common stock issued pursuant to stock option exercises (in shares)						63,894
Common stock issued pursuant to stock option exercises	678		678
Stock-based compensation expense	17,559		17,559
Vested restricted stock units converted to common stock (in shares)						12,072
Ending balance, preferred stock (in shares) at Mar. 31, 2022		0
Ending balance at Mar. 31, 2022	$ 329,444	$ 0	981,780	(652,337)		$ 1
Ending balance, common stock (in shares) at Mar. 31, 2022						7,428,924
Beginning balance, preferred stock (in shares) at Dec. 31, 2022	0	0
Beginning balance at Dec. 31, 2022	$ 253,705	$ 0	1,378,125	(1,124,421)		$ 1
Beginning balance, common stock (in shares) at Dec. 31, 2022	11,773,065					11,773,065
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (60,989)
Common stock issued pursuant to stock option exercises (in shares)					50,444	50,444
Common stock issued pursuant to stock option exercises	266		266
Stock-based compensation expense	48		48
Vested restricted stock units converted to common stock (in shares)						54,175
Issuance of Class A common shares in underwritten public offering, net of issuance costs (in Shares)						12,315,752
Issuance of Class A common shares in underwritten public offering, net of issuance costs	$ 135,439		135,438			$ 1
Ending balance, preferred stock (in shares) at Mar. 31, 2023	0	0
Ending balance at Mar. 31, 2023	$ 328,469	$ 0	$ 1,513,877	$ (1,185,410)		$ 2
Ending balance, common stock (in shares) at Mar. 31, 2023	24,193,436					24,193,436

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net loss	$ (60,989)	$ (76,896)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	8,636	5,803
Impairment loss	2,120	0
Gain on debt forgiveness	(2,750)	0
Stock-based compensation expense	48	17,559
Change in fair value of warrant and earn-out contingent liabilities	3,453	(13,190)
Deferred tax benefit	(147)	0
Provision for excess and obsolete inventory	0	43
Non-cash lease expense	146	167
Amortization of deferred debt issuance costs	128	128
Change in operating assets and liabilities:
Accounts receivable	9,723	(11,132)
Inventory	1,331	(2,904)
Prepaid expenses and other current assets	4,232	1,596
Due to/from related parties	793	543
Other assets	(55)	(151)
Accounts payable and accrued expenses	(14,470)	3,932
Contract liabilities	0	(408)
Other current liabilities	(7,759)	(6,584)
Net cash used in operating activities	(55,560)	(81,494)
Investing activities
Purchases of property and equipment	0	(1,378)
Development of internal-use software assets	(462)	(2,535)
Net cash used in investing activities	(462)	(3,913)
Financing activities
Proceeds from underwritten public offering, net of issuance costs	135,439	0
Long-term debt principal payment	(2,000)	0
Finance lease payoff	(438)	0
Finance lease principal payments	(609)	(862)
Exercise of stock options	266	702
Net cash provided by (used in) financing activities	132,658	(160)
Net increase (decrease) in cash, cash equivalents and restricted cash	76,636	(85,567)
Cash, cash equivalents and restricted cash, at beginning of period	138,303	401,469
Cash, cash equivalents and restricted cash, at end of period	214,939	315,902
Supplemental disclosures of cash flow information
Cash paid for interest	583	607
Cash paid for taxes	104	168
Purchases of property and equipment in accounts payable and accrued expenses	1,073	1,325
Software development costs in accounts payable and accrued expenses	157	717
Unpaid deferred transaction costs included in accounts payable and accrued expenses	$ 0	$ 227

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business GeneDx Holdings Corp. (“GeneDx Holdings”) through its subsidiaries Sema4 OpCo, Inc., formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”) and GeneDx, LLC, provides genomics-related diagnostic and information services and pursues genomics medical research. GeneDx utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, and screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings’ operating subsidiaries primarily serve healthcare professionals who work with their patients and bills third-party payors across the United States. On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Business Combination Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Business Combination Merger” and, together with the other transactions contemplated by the Business Combination Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” (“Sema4 Holdings”) and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration. The Business Combination Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Business Combination Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination Merger (1 share of Legacy Sema4 Class A common stock for 4.0000 shares of Sema4 Holdings Class A common stock (the “Class A common stock”) (the “Conversion Ratio”). Prior to the Business Combination Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. In addition, on April 29, 2022, the Company consummated the transactions contemplated by that certain Agreement and Plan of Merger, dated as of January 14, 2022 (as amended, the “ Acquisition Merger Agreement”), by and among the Company and GeneDx, Inc. (“Legacy GeneDx”), a New Jersey corporation and wholly-owned subsidiary of OPKO Health, Inc. (“OPKO”), GeneDx Holding 2, Inc., which held 100% of Legacy GeneDx (“Holdco2”), at the Effective Time (as defined in the Acquisition Merger Agreement) and OPKO, which provided for, among other things, the acquisition of Legacy GeneDx from OPKO. After giving effect to the mergers and the other transactions contemplated by the Acquisition Merger Agreement (the “Acquisition”), Legacy GeneDx was converted into a Delaware limited liability company and became the Company’s wholly-owned indirect subsidiary. See Note 3, “Business Combination,” for additional details regarding the Business Combination and Acquisition. On January 9, 2023, Sema4 Holdings Corp. changed its name to GeneDx Holdings Corp. Upon the name change, the Company’s Class A common stock and public warrants are listed on the Nasdaq under the symbols “WGS” and “WGSWW,” respectively. On May 4, 2023, the Company effected a reverse stock split of its Class A common stock at a ratio of 1-for-33 (the “Reverse Stock Split”). Unless otherwise noted, all share amounts, exercise prices and other amounts set forth herein have been adjusted for the impact of the Reverse Stock Split. Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “GeneDx” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) GeneDx Holdings and its subsidiaries following the consummation of the Business Combination (including, following the consummation of the Acquisition, Legacy GeneDx).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. As such, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto as of and for the years ended December 31, 2022, 2021 and 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 21, 2022 filed on March 16, 2023 (the “Annual Report”). The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to state fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results of operations or cash flows for a full year or any subsequent interim period. The Company’s historical financial information includes costs of certain services historically provided by Icahn School of Medicine at Mount Sinai (“ISMMS”) pursuant to a Transition Services Agreement (“TSA”) and service agreements. See Note 7, “Related Party Transactions”. Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the date of filing of this Quarterly Report on Form 10-Q. Reverse Stock Split On May 4, 2023, at the commencement of trading, the Company effected a 1-for-33 reverse stock split. Accordingly, all share and per share amounts for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split. Reclassifications Certain reclassifications have been made to the prior year unaudited condensed consolidated financial statements in order to conform to the current year’s presentation. Summary of Significant Accounting Policies There have been no material changes to the Company’s critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the Company’s audited consolidated financial statements and notes thereto included within its Annual Report on Form 10-K for the year ended December 31, 2022. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the capitalization of software costs, the valuation of stock-based awards, inventory, earn-out contingent liabilities and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The majority of the Company’s cash, cash equivalents and restricted cash are uninsured with account balances in excess of the Federal Deposit Insurance Company limits. As of March 31, 2023, 100% of the Company’s cash, cash equivalents and marketable securities was held in high-quality institutions designated as systematically important financial institutions. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant patients and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of March 31, 2023 and December 31, 2022 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient or client that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate patient or payor credit risk. For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows: Revenue Accounts Receivable Three months ended March 31, As of March 31, As of December 31, 2023 2022 2023 2022 Payor A * 24% * * Payor B (1) 15% * * 14% Payor D * 10% * * Payor E 24% * 15% 14% *less than 10% __________________ (1) This payor includes multiple individual plans and the Company calculates and presents the aggregated value from all plans, which is consistent with the Company’s portfolio approach used in accounting for diagnostic test revenue. The Company is subject to a concentration of risk from a limited number of suppliers for certain reagents and laboratory supplies. One supplier accounted for approximately 14% and 13% of purchases for the three months ended March 31, 2023 and 2022, respectively. This risk is managed by maintaining a target quantity of surplus stock. Alternative suppliers are available for some or all of these reagents and supplies. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds. Carrying values of cash equivalents approximate fair value due to the short-term nature of these instruments. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): As of March 31, 2023 As of December 31, 2022 Cash and cash equivalents $ 201,895 $ 123,933 Restricted cash 13,044 14,370 Total $ 214,939 $ 138,303 Restricted cash as of March 31, 2023 includes $12.1 million held in escrow as restricted cash related to the closing of the Acquisition which is expected to be released upon expiration of the one year escrow period in May 2023. During the three months ended March 31, 2023, the Company has completed the net working capital settlement with OPKO and received $1.3 million of the restricted cash that was recorded as of December 31, 2022. In addition, restricted cash as of March 31, 2023 consists of money market deposit accounts that secure an irrevocable standby letter of credit that serves as collateral for security deposit operating leases (see Note 9, “Leases” ). Accounts Receivable Accounts receivable consists of amounts due from customers and third-party payors for services performed and reflect the consideration to which the Company expects to be entitled in exchange for providing those services. Accounts receivable are estimated and recorded in the period the related revenue is recorded. The accounts receivable balance as of March 31, 2023 and December 31, 2022 included $2.9 million and $1.5 million, respectively, of unbilled receivables. During the quarter ended March 31, 2023, the Company did not record provisions for doubtful accounts. The Company did not write off any accounts receivable balances for the period. Inventory, net Inventory, net, which primarily consists of finished goods such as testing supplies and reagents, is capitalized when purchased and expensed when used in performing services. Inventory is stated at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The Company periodically performs obsolescence assessments and writes off any inventory that is no longer usable. Any write-down of inventory to net realizable value creates a new cost basis. Fair Value Measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. The following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market: Level 1 : Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 : Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active or model-derived valuations whose significant inputs are observable. Level 3 : Unobservable inputs that are significant to the measurement of fair value but are supported by little to no market data. The Company’s financial assets and liabilities consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short-term nature of these accounts. The Company’s loan from the Connecticut Department of Economic and Community Development is classified within level 2 of the fair value hierarchy. As of March 31, 2023, this loan is recorded at its carrying value of $6.3 million in the consolidated balance sheet. The fair value of the loan is $5.1 million, which is estimated based on discounted cash flows using the yields of similar debt instruments of other companies with similar credit profiles. Warrant Liability As of the consummation of the Business Combination Merger in July 2021, there were 666,516 warrants to purchase shares of Class A common stock outstanding, including 447,223 public warrants and 219,293 private placement warrants. As of December 31, 2022, there were 666,515 warrants to purchase shares of Class A common stock outstanding, including 447,222 public warrants and 219,293 private placement warrants outstanding. Each warrant expires five years after the Business Combination or earlier upon redemption or liquidation, and entitles the holder to purchase one share of Class A common stock at an exercise price of $379.50 per share, subject to adjustment, at any time commencing on September 4, 2021. The Company may redeem the outstanding public warrants if the price per share of the Class A common stock equals or exceeds $594.00 as described below: • in whole and not in part; • at a price of $0.33 per public warrant; • upon not less than 30 days’ prior written notice of redemption to each warrant holder; and • if, and only if, the closing price of the Class A common stock equals or exceeds $594.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before sending the notice of redemption to warrant holders. The Company may redeem the outstanding public warrants if the price per share of the common stock equals or exceeds $330.00 as described below: • in whole and not in part; • at $3.30 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the common stock; • if, and only if, the closing price of the Class A common stock equals or exceeds $330.00 per share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and • if the closing price of the common stock for any 20 trading days within a 30-trading day period ending three trading days before the Company sends notice of redemption to the warrant holders is less than $594.00 per share (as adjusted), the private placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above. The private placement warrants were issued to CMLS Holdings, LLC, Mr. Munib Islam, Dr. Emily Leproust and Mr. Nat Turner, and are identical to the public warrants underlying the units sold in the initial public offering, except that (1) the private placement warrants and the common stock issuable upon the exercise of the private placement warrants would not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (2) the private placement warrants are exercisable on a cashless basis, (3) the private placement warrants are non-redeemable (except as described above, upon a redemption of warrants when the price per share of Class A common stock equals or exceeds $330.00) so long as they are held by the initial purchasers or their permitted transferees, and (4) the holders of the private placement warrants and the common stock issuable upon the exercise of the private placement warrants have certain registration rights. If the private placement warrants are held by someone other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by the Company and exercisable by such holders on the same basis as the public warrants. The Company accounts for warrants as liability-classified instruments based on an assessment of the warrant terms and applicable authoritative guidance in accordance with ASC 480-Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Contingent Consideration (Legacy GeneDx) In connection with the Acquisition, up to $150 million of contingent payments will be payable to OPKO in cash and/or shares of Company’s Class A common stock with such mix to be determined in the Company’s sole discretion, based upon achievement of 2022 and 2023 revenue milestones, pursuant to the Acquisition Merger Agreement (the “Milestone Payments”). If the Company elects to pay in shares of Class A common stock, the Acquisition Merger Agreement provides that the shares issues are to be valued at $160.38 per share for a maximum of 935,280 shares. Subject to the terms and conditions of the Acquisition Merger Agreement, (a) the first Milestone Payment was paid out in full through the issuance of 701,460 shares valued at $112.5 million in April 2023 as the revenue of the Legacy GeneDx group for the fiscal year 2022 exceeded $163 million and (b) the second Milestone Payment of $37.5 million will become due and payable if the revenue of the Legacy GeneDx group for the fiscal year 2023 equals or exceeds $219 million (each of clauses (a) and (b), a “Milestone Event”); provided that 80% of the second Milestone Payment will become payable in respect of the second milestone period if the Legacy GeneDx group achieves 90% of the Milestone Event revenue target for such period, which amount will scale on a linear basis up to 100% of the second Milestone Payment at 100% of the revenue target. The first Milestone Payment resulted in the issuance of 701,460 shares of the Company’s Class A common stock on April 14, 2023; see Note 18, “Subsequent Events.” If the Company elects to pay in shares of Class A Common stock, the second Milestone Payment would require the issuance of up to 233,820 shares of the Company’s Class A common stock. The fair value of the second Milestone Payment was determined to be $2.6 million as of March 31, 2023 and is estimated using a Monte Carlo simulation valuation model and assuming the Company will pay the Milestone Payment in shares. Earn-out Contingent Liability In connection with the Business Combination Merger, all Legacy Sema4 stockholders and option holders at that time became entitled to a pro rata share of 576,412 earn-out shares and earn-out RSUs. Based on an assessment of the earn-out shares for the Legacy Sema4 stockholders, the Company considered ASC 480 and ASC 815 and accounted for the earn-out shares as a liability. The Company subsequently measures the fair value of the liability at each reporting period and reports the changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The Company determined that the fair value of the earn-out shares issued to the Legacy Sema4 stockholders as of March 31, 2023 was zero. The estimated fair value of the earn-out is determined using a Monte Carlo simulation valuation model. As for the earn-out RSUs for the Legacy Sema4 option holders, a total of 81,819 RSUs were granted on December 9, 2021. The vesting of such arrangement is conditioned on the satisfaction of both a service requirement and on the satisfaction of a market-based requirement. The market-based requirement would be achieved if the Company’s stock price is greater than or equal to $429 (Triggering Event I), $495 (Triggering Event II) and $594 (Triggering Event III) during the applicable performance period, based on the volume-weighted average price for a period of at least 20 days out of 30 consecutive trading days. Therefore, the Company accounts for this arrangement in accordance with ASC 718- Compensation — Stock Compensation (“ASC 718”) and stock-based compensation expense is recognized over the longer of the expected achievement period for the market-based requirement and the service requirement. The Company recorded $0.8 million reduction in stock-based compensation expense in relation to the forfeiture of the earn-out RSUs by the Legacy Sema4 option holders for the three months ended March 31, 2023. In the event that any earn-out RSUs that are forfeited as a result of a failure to achieve the service requirement, the underlying shares will be reallocated on an annual basis to the Legacy Sema4 stockholders and to the Legacy Sema4 option holders who remain employed as of the date of such reallocation. The Company accounts for the re-allocations to Legacy Sema4 option holders as new grants. These earn-out arrangements will expire in July 2023 if the market-based requirement is not met. Segment Information Historically, the Company operated in one segment. During 2022, in connection with the Acquisition, the change in Chief Operating Decision Maker (“CODM”), and the announced exit from the majority of the Legacy Sema4 diagnostics operations, the Company’s CODM began to evaluate the Company’s business separately for GeneDx, inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs and corporate support costs, and the existing Legacy Sema4 diagnostics business during the fourth quarter of 2022. As a result, the Company has concluded that two reportable segments exist and have been presented as such for the first quarter of 2023. The majority of the Company’s operations for the first quarter of 2022 are included in the Legacy Sema4 segment and the majority of the GeneDx segment for 2022 was resultant from the Acquisition in 2022, and thus did not exist within the Company’s condensed consolidated results for the first quarter of 2022. As a result, the Company has not presented segments for the first quarter of 2022. See Note 16, “ Segment Reporting ”, for the first quarter of 2023 segment disclosures. Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The new credit losses standard changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, contract assets recognized as a result of applying ASC 606, loans and certain other instruments, entities will be required to use a new forward looking “expected loss” model that generally will result in earlier recognition of credit losses than under today’s incurred loss model. The Company adopted ASU 2016-13 effective January 1, 2023 and the adoption did not have material impact in the condensed consolidated statements of operations and comprehensive loss. Recently Issued Accounting Pronouncements Not Yet Adopted The Company has reviewed the recently issued Accounting Standards Update accounting pronouncements and does not believe that the adoption of any such pronouncements will have a material impact on its financial statements or related disclosures.

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations CMLS/Legacy Sema4 Business Combination On July 22, 2021, the Company consummated the Business Combination (as defined in Note 1) and received net cash proceeds of $510.0 million. Pursuant to the Business Combination, the following occurred: • Holders of 309 shares of CMLS’s Class A common stock sold in its initial public offering (the “public shares”) exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from CMLS’s initial public offering (the “IPO”), which was approximately $330.00 per share, or $101,880 in aggregate. • Each share of CMLS’s Class B common stock was automatically converted into common stock of the Company. • Each share of the Legacy Sema4 Class B common stock was converted into 1/100 th of a share of Legacy Sema4 Class A common stock and each share of Legacy Sema4 common stock and preferred stock was canceled and received a portion of the merger consideration, resulting in certain Legacy Sema4 stockholders receiving $230.7 million of cash and the Legacy Sema4 stockholders receiving an aggregate of 5,404,131 shares of common stock of the Company. • Pursuant to subscription agreements entered into on February 9, 2021, certain investors agreed to subscribe for an aggregate of 1,060,607 newly-issued shares of Class A common stock at a purchase price of $330.00 per share for an aggregate purchase price of $350,000,000 (the “Business Combination PIPE Investment”). Concurrently with the closing of the Business Combination, the Company consummated the Business Combination PIPE Investment. • After giving effect to the Business Combination Merger, the redemption of public shares and the conversion of the CMLS Class B common stock as described above, and the consummation of the Business Combination PIPE Investment, there were 7,278,498 shares of the Company’s Class A common stock issued and outstanding. In 2021, the Company recorded $51.8 million of transaction costs which consisted of direct, incremental legal, professional, accounting, and other third-party fees that were directly related to the execution of the Business Combination Merger in additional paid-in capital. Upon consummation of the Business Combination Merger, $9.0 million of the transaction costs relates to costs incurred by Legacy Sema4 and reclassed to offset against equity from prepaid expense and other current assets. Legacy GeneDx Acquisition As discussed in Note 1, on April 29, 2022, the Company completed the Acquisition. At the closing of the Acquisition, the Company paid OPKO gross cash consideration of $150 million (before deduction of transaction expenses and other customary purchase price adjustments) and issued to OPKO 2.4 million shares of the Company’s Class A common stock ($172 million based on the closing date share price of $70.95 per share). A portion of this cash and stock consideration is held in escrow and is expected to be released upon expiration of the one year escrow period in May 2023. During the three months ended March 31, 2023, the Company has completed the net working capital settlement with OPKO which resulted in a reduction of $1.3 million of other current assets that was previously recorded as of December 31, 2022. In addition, a portion of the $150 million was payable following the closing of the Acquisition due to the achievement of the first revenue-based milestone for the fiscal year ended December 31, 2022 and the remaining milestone payment up to $37.5 million will be payable if certain revenue-based milestones are achieved for the fiscal year ending December 31, 2023. These milestone payments, if and to the extent earned under the terms of the Acquisition Merger Agreement, will be satisfied through the payment and/or issuance of a combination of cash and shares of the Company’s Class A common stock (valued at $160.38 per share, subject to adjustment for stock splits and similar changes), with such mix to be determined in the Company’s sole discretion. As discussed in Note 18, “Subsequent Events.” the first Milestone Payment became due and payable in full and resulted in the issuance of 701,460 shares of the Company’s Class A common stock on April 14, 2023. Concurrently with the closing of the Acquisition, the Company also issued and sold in private placement 1,515,152 shares of the Company’s Class A common stock to certain institutional investors for aggregate gross proceeds of $200 million (the “Acquisition PIPE Investment”). The following table presents the net purchase price and the fair values of the assets and liabilities of Legacy GeneDx on a preliminary basis (in thousands): Cash and cash equivalents $ — Accounts receivables 21,651 Inventory 6,210 Prepaid expenses 4,671 Other current assets 320 Property and equipment 29,509 Other non-current assets 6,464 Trade names and trademarks 50,000 Developed technology 48,000 Customer relationships 98,000 Accounts payable and accrued expenses (12,862) Other current liabilities (15,781) Deferred tax liabilities (51,779) Long-term lease liabilities (5,798) Fair value of net assets acquired 178,605 Goodwill (1) 185,871 Aggregate purchase price $ 364,476 (1) Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. See Note 17, “Goodwill and Intangible Assets” for more detail. The amounts above represent the preliminary fair value estimates at the time of the Acquisition and the Company has identified certain adjustments during the measurement period. These measurement period adjustments are reflected in the goodwill balance and shown in Note 17, “ Goodwill and Intangible Assets

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregated revenue The following table summarizes the Company’s disaggregated revenue by payor category (in thousands): Three months ended March 31, 2023 2022 Diagnostic test revenue Patients with third-party insurance $ 25,329 $ 47,462 Institutional customers 16,060 4,031 Self-pay patients 461 1,002 Total diagnostic test revenue 41,850 52,495 Other revenue 1,289 1,446 Total $ 43,139 $ 53,941 Reassessment of variable consideration Subsequent changes to the estimate of the transaction price, determined on a portfolio basis when applicable, are generally recorded as adjustments to revenue in the period of the change. The Company updates estimated variable consideration quarterly. For the three months ended March 31, 2023 and 2022, the quarterly change in estimate resulted in a net $2.7 million and $3.6 million increase, respectively, to revenue for tests in which the performance obligation of delivering the test results was met in prior periods. The change in estimate is a result of changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. The change in estimate also included an increase in revenue related to a partial release of a previously established payor reserve, as further disclosed in the “—Certain payor matters” below. The quarterly change in estimate did not result in material adjustments to the Company’s previously reported revenue or accounts receivable amounts. Certain payor matters As noted above, third-party payors, including government programs, may decide to deny payment or seek to recoup payments for tests performed by the Company that they contend were improperly billed, not medically necessary or against their coverage determinations, or for which they believe they have otherwise overpaid, including as a result of their own error. As a result, the Company may be required to refund payments already received, and the Company’s revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance, and changes by government agencies and payors in interpretations, requirements, policies and/or “conditions of participation” in various programs. The Company processes requests for recoupment from third-party payors in the ordinary course of its business, and it is likely that the Company will continue to do so in the future. If a third-party payor denies payment for testing or recoups money from the Company in a later period, reimbursement and the associated recognition of revenue for the Company’s testing services could decline. As an integral part of the Company’s billing compliance program, in the third quarter of 2022, the Company instituted a third-party review of billing claims and compliance practices, and initiated improvements including implementing a package of new billing compliance policies and procedures and strengthening the Company’s billing compliance team. From time to time, the Company may have an obligation to reimburse Medicare, Medicaid, and third-party payors for overpayments regardless of fault. Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing services. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, the Company’s historical settlement activity (if any), and the Company’s assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved. Estimated settlements are adjusted in future periods as such adjustments become known (that is, if new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Throughout 2022, the Company was engaged in discussions with one of its third-party payors (the “Payor”) regarding certain overpayments to Legacy Sema4. On December 30, 2022, the Company entered into a settlement agreement with the Payor in order to settle the claims related to coverage and billing matters allegedly resulting in the overpayments to Legacy Sema4 by the Payor to the Company (the “Disputed Claims”). Under the settlement agreement, $42.0 million is to be paid by the Company to the Payor in a series of installments over the next four years with the final installment payment scheduled to be on or before June 30, 2026. The first installment payment of $15.0 million was made on December 31, 2022 and the next installment of $5.0 million is due in December 2023. In consideration for these payments, the Payor has agreed to provide releases of the Disputed Claims, which releases became effective on or about March 31, 2023. As a result of this matter, and in connection with a review of certain billing policies and procedures undertaken by management, the Company considered the need to establish reserves for potential recoupments of payments previously made by third-party payors. As of March 31, 2023, the Company continued to carry liabilities that were initially established as of June 30, 2022 as a result of this matter and other potential settlements with payors, as adjusted as of March 31, 2023, based on the current facts and an evaluation of anticipated results that the Company believes reasonable for all potential recoupments for all third-party payors combined. As of March 31, 2023 and December 31, 2022, $37.9 million and $39.0 million of liabilities were recorded in accounts payable and accrued expenses and other liabilities, respectively. See Note 15, “Supplemental Financial Information”. The Company uses estimates, judgments, and assumptions to assess whether it is probable that a significant reversal in the amount of cumulative revenue may occur in future periods, based upon information presently available. These estimates are subject to change. In addition, as discussed above, the Company has made certain adjustments to its estimated variable consideration as result of this matter and other potential settlements with payors. Remaining performance obligations For certain long-term collaboration service agreements with original expected durations of more than one year, the Company’s obligations pursuant to such agreement represents partially unsatisfied performance obligations as of March 31, 2023. The revenues under the agreements are estimated to be approximately $6.0 million. The Company expects to recognize the majority of this revenue over the next 2.3 years. Costs to fulfill contracts Costs associated with fulfilling the Company’s performance obligations pursuant to its collaboration service agreements include costs for services that are subcontracted to ISMMS. Amounts prepaid are expensed in line with the pattern of revenue recognition. Prepayment of amounts prior to the costs being incurred are recognized in the condensed consolidated balance sheets as current or non-current based upon forecasted performance. As of March 31, 2023 and December 31, 2022, the Company had outstanding deferred costs to fulfill contracts of less than $0.1 million and $0.3 million, respectively, which were recorded as other current assets in the condensed consolidated balance sheets. The Company expect to make additional payments to ISMMS under an amended subcontract agreement with ISMMS. Amortization of deferred costs was $0.6 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively. The amortization costs were recorded in the cost of services in the condensed consolidated statements of operations and comprehensive loss.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. The following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active or model-derived valuations whose significant inputs are observable. Level 3: Unobservable inputs that are significant to the measurement of fair value but are supported by little to no market data. The Company’s financial assets and liabilities consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, finance leases, warrant liability, earn-out contingent liabilities, contingent consideration based on milestone achievement, and long-term debt. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short-term nature of these accounts. The Company’s finance leases are classified within Level 1 of the fair value hierarchy because such finance lease agreements bear interest at rates for instruments with similar characteristics; accordingly, the carrying value of these liabilities approximate their fair values. The Company’s loan from the Connecticut Department of Economic and Community Development is classified within Level 2 of the fair value hierarchy. As of March 31, 2023, the loan was recorded at its carrying value of $6.3 million with no current portion recorded as there are no principal payments due until August 2024. The fair value was $5.1 million, which is estimated based on discounted cash flows using the yields of similar debt instruments of other companies with similar credit profiles. The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands): As of March 31, 2023 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 45,069 $ 45,069 $ — $ — Total financial assets $ 45,069 $ 45,069 $ — $ — Financial Liabilities: Public warrant liability $ 295 $ 295 $ — $ — Private warrant liability 145 — 145 — DECD loan 5,110 — 5,110 — Contingent consideration based on milestone achievement 11,049 — — 11,049 Total financial liabilities $ 16,599 $ 295 $ 5,255 $ 11,049 As of December 31, 2022 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 16,901 $ 16,901 $ — $ — Total financial assets $ 16,901 $ 16,901 $ — $ — Financial Liabilities: Public warrant liability $ 280 $ 280 $ — $ — Private warrant liability 138 — 138 — DECD loan 4,904 — 4,904 — Contingent consideration based on milestone achievement 7,619 — — 7,619 Total financial liabilities $ 12,941 $ 280 $ 5,042 $ 7,619 The Company’s outstanding warrants include publicly traded warrants (the “Public Warrants”) which were originally issued in the IPO and warrants sold in a private placement to CMLS Holdings LLC (the “Private Warrants”). The Company evaluated its warrants under ASC 815-40-Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders’ equity. Since the Public Warrants and Private Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as non-current liabilities on the balance sheet at fair value upon the closing of the Business Combination, with subsequent changes in their respective fair values recognized in other income in the condensed consolidated statements of operations and comprehensive loss at each reporting date. As of March 31, 2023, the Public Warrants are classified within Level 1 of the fair value hierarchy as they are traded in active markets. The Private Warrants are classified within Level 2 of the fair value hierarchy as management determined the fair value of each Private Warrant is the same as that of a Public Warrant because the terms are substantially the same. For the quarter ended March 31, 2023, a loss of $3.5 million was recorded within the change in fair market value of warrant and earn-out contingent liabilities in the consolidated statements of operations and comprehensive loss based on remeasurement performed as of the period end date. The earn-out contingent liabilities include the Company’s contingent obligation to issue earn-out shares for Legacy Sema4 stockholders (“Earn-out Shares”) as well as the Company’s obligation to pay out the first Milestone Payment of $112.5 million to OKPO and the contingent obligation to make an additional second Milestone Payment of up to $37.5 million to OPKO if a certain revenue-based milestone is achieved for the fiscal year ended December 31, 2023. The Earn-out Shares are accounted for as a liability and required remeasurement at each reporting date. The estimated fair value of the total Earn-out Shares as of March 31, 2023 is determined based on a Monte Carlo simulation valuation model. The fair value of the earn-out contingent liability is sensitive to the expected volatility for the Company and the Company’s Class A common stock price which is sensitive to changes in the forecasts of earnings and/or the relevant operating metrics. The expected volatility for the Company is based on the historical volatility of selected guideline companies, the historical volatility of the Company, and the implied volatility of the Company’s call options. The key assumptions utilized in determining the Earn-out Shares valuation as of March 31, 2023 and December 31, 2022 were as follows: March 31, 2023 December 31, 2022 Stock price $12.21 $8.58 Expected volatility 120.0% 107.5% Expected term (in years) 0.3 0.6 Risk-free interest rate 4.87% 4.76% The fair value determined and recorded as of March 31, 2023 and December 31, 2022 was zero. During the three months ended March 31, 2023 and 2022, $0 gain or loss was recognized and $6.8 million was recorded, respectively, in the change in fair market value of warrant and earn-out contingent liability in the condensed consolidated statements of operations and comprehensive loss based on re-measurement performed as of the period end date. The Milestone Payment contingent liability represents additional acquisition consideration to pay up to $37.5 million based on the achievement of Legacy GeneDx revenue-based milestone in fiscal year 2023 and the obligation to payout the first milestone of $112.5 million in shares of the Company’s Class A common stock. Subject to the terms and conditions of the Acquisition Merger Agreement, (a) the first Milestone Payment of $112.5 million became due and payable in full as Legacy GeneDx revenue exceeded $163 million for the fiscal year 2022 and (b) the second Milestone Payment of $37.5 million will become due and payable if the revenue of the Legacy GeneDx group for the fiscal year 2023 equals or exceeds $219 million; provided that 80% of the second Milestone Payment will become payable in respect of the second milestone period if the Legacy GeneDx group achieves 90% of the Milestone Event revenue target for such period, which amount will scale on a linear basis up to 100% of the second Milestone Payment at 100% of the revenue target. The first Milestone Payment resulted in the issuance of 701,460 shares of the Company’s Class A common stock on April 14, 2023; see Note 18, “Subsequent Events.” The second Milestone Payment will be satisfied through the payment and/or issuance of a combination of cash and shares of the Company’s Class A common stock (valued at $160.38 per share), with such mix to be determined at the Company’s sole discretion. The Company determined and recorded the fair value of the Milestone Payments as $11.0 million as of March 31, 2023, of which the first milestone payment of $8.4 million is presented as current liabilities in the condensed consolidated balance sheets. For the three months ended March 31, 2023 a loss of $3.4 million was recorded in the change in fair market value of warrant and earn-out contingent liabilities in the condensed consolidated statements of operations and comprehensive loss based on re-measurement performed as of the period end date. The fair value of the second milestone was determined based on a Monte Carlo simulation valuation model and the key assumptions include revenue projections, revenue volatility of 18%, the Company’s expectation to settle the liability in shares and share price of $12.21 per share. The fair value of the first milestone was determined based on the Company’s expectation to settle the liability in shares and share price of $12.21 per share.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment, net consisted of the following (in thousands): As of March 31, As of December 31, Laboratory equipment $ 42,370 $ 41,255 Equipment under finance leases 21,384 21,384 Leasehold improvements 35,560 35,561 Capitalized software 32,171 32,171 Building under finance lease 8,059 6,276 Construction in-progress 3,533 3,386 Computer equipment 9,185 9,177 Furniture, fixtures and other equipment 3,777 3,777 Total property and equipment 156,039 152,987 Less: accumulated depreciation and amortization (106,531) (101,460) Property and equipment, net $ 49,508 $ 51,527 For the three months ended March 31, 2023 and 2022, depreciation and amortization expense was $5.1 million and $5.8 million, respectively. This included software amortization expense of $1.0 million and $1.6 million for the three months ended March 31, 2023 and 2022, respectively. For intangible amortization, see Note 17, “Goodwill and Intangible Assets.” The Company identified indicators of impairment specifically with the modification of the sublease agreement, see Note 9, “Leases.” As a result, the Company recorded a $1.6 million impairment charge within impairment loss in the Company’s condensed consolidated statements of operations and comprehensive loss for the quarter ended March 31, 2023, of which $0.8 million was allocated to the building under finance lease associated with the sublease. Depreciation and amortization expense is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2023 2022 Cost of services $ 589 $ 2,816 Research and development 852 1,849 Selling and marketing 2 1 General and administrative 3,687 1,137 Total depreciation and amortization expenses $ 5,130 $ 5,803

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party revenues Related party revenues primarily include diagnostic testing revenues generated by GeneDx from BioReference Laboratories, Inc. (“BRLI”), which is a subsidiary of OPKO. The prices charged represent market rates. Revenue recorded from this contract was $0.7 million and $0 for the three months ended March 31, 2023 and 2022, respectively. Related party expenses On June 1, 2017, the Company signed a contribution and funding agreement and other agreements with ISMMS, whereby ISMMS contributed certain assets and liabilities related to the Company’s operations, provided certain services to the Company, and also committed to funding the Company up to $55.0 million in future capital contributions in exchange for equity in the Company, of which $55.0 million was drawn as of December 31, 2019. Following the transaction, the Company commenced operations and began providing the services and performing research. Expenses recognized pursuant to service arrangements with ISMMS, including certain sub-lease arrangements the Company has through ISMMS, totaled $1.9 million for the three months ended March 31, 2023 and 2022. These amounts include certain lease expenses the Company incurs and pay to ISMMS for certain sub-lease arrangements. They are included in either cost of services or related party expenses in the condensed consolidated statements of operations and comprehensive loss depending on the particular activity to which the costs relate. Payables due to ISMMS for the other service arrangements were $3.1 million and $2.4 million as of March 31, 2023 and December 31, 2022, respectively, these amounts include unpaid lease payments the Company accrued for. The payments to be made to ISMMS and are included within due to related parties on the Company’s condensed consolidated balance sheets. Additionally, the Company has purchased $0.5 million of diagnostic testing kits and materials and less than $0.1 million was recorded in cost of services for the three months ended March 31, 2023 from an affiliate of a member of the Board of Directors who has served in the role since July 2021. The prices paid represent market rates. Payables due were $0.4 million as of March 31, 2023 and December 31, 2022. Legacy GeneDx and OPKO entered into a Transition Services Agreement dated as of April 29, 2022 (the “OPKO TSA”) pursuant to which OPKO has agreed to provide, at cost, certain services in support of the Acquisition of the Legacy GeneDx business through December 31, 2022, subject to certain limited exceptions, in order to facilitate the transactions contemplated by the Acquisition Merger Agreement, including human resources, information technology support, and finance and accounting. The Company recorded $0.8 million for the three months ended March 31, 2023 related to the agreement. As of March 31, 2023 there were $0.6 million unpaid costs and at December 31, 2022 $0.4 million was unpaid and included in due to related parties in condensed consolidated balance sheets. During the three months ended March 31, 2023, the Company recorded a reduction of $1.3 million receivables from OPKO related to the Acquisition closing working capital adjustment that was previously recorded as of December 31, 2022. The amount was presented as other current assets in condensed consolidated balance sheets as of December 31, 2022. Total related party costs are included within cost of services and related party expenses in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2023 2022 Cost of services $ 815 $ 1,056 Related party expenses 1,747 1,284 Total related party costs $ 2,562 $ 2,340

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Loan and Security Agreement (the “SVB Agreement”) On November 15, 2021, the Company and Sema4 OpCo, Inc. (together, the “Borrower”) entered into a Loan and Security Agreement (the “SVB Agreement”) with Silicon Valley Bank (“SVB”). The SVB Agreement provides for a revolving credit facility (the “Revolver”) up to an aggregate principal amount of $125.0 million, including a sublimit of $20.0 million for Letters of Credit (as such terms are defined in the SVB Agreement). The outstanding principal amount of any Advance (as such term is defined in the SVB Agreement) will bear interest at a floating rate per annum equal to the greater of (1) 4.00% and (2) the Prime Rate plus the Prime Rate Margin. The Revolver will mature on November 15, 2024. In connection with entering into the SVB agreement, the Company paid $0.5 million in debt issuance costs during 2021. The Company will pay an additional $0.5 million in fees to SVB at each anniversary of the SVB Agreement date for a total of $1.0 million and these fees are recorded in other current liabilities and other liabilities in the condensed consolidated balance sheets as of March 31, 2023. These costs are capitalized and amortized on a straight-line basis over the contractual term. Any unused fees charged on the Revolver is expensed as incurred. The obligations under the SVB Agreement are secured by a first priority perfected security interest in substantially all of the Borrower’s assets except for (i) Governmental Collection Accounts (as defined in the SVB Agreement), (ii) more than 65% of the presently existing and thereafter arising issued and outstanding shares of capital stock owned by Borrowers in a Foreign Subsidiary (as such term is defined in the SVB Agreement) and (iii) intellectual property pursuant to the terms of the SVB Agreement. The SVB Agreement contains affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, and dividends and other distributions. The SVB Agreement requires the Borrower to comply with certain financial covenants if Liquidity (as such term is defined in the SVB Agreement) falls below $135.0 million. These financial covenants include (i) a minimum Adjusted Quick Ratio (as such term is defined in the SVB Agreement) and (ii) the achievement of certain minimum revenue targets. On a monthly basis, the Borrowers would be required to maintain a minimum Adjusted Quick Ratio of greater than or equal to 1.25 to 1.0. The Borrower must also maintain certain trailing six-month minimum revenue targets through maturity if outstanding borrowings under the Revolver exceed $50.0 million. The SVB Agreement also includes customary events of default, including failure to pay principal, interest or certain other amounts when due, material inaccuracy of representations and warranties, violation of covenants, certain bankruptcy and insolvency events, certain undischarged judgments, material invalidity of guarantees or grant of security interest, material adverse change, and involuntary delisting from the Nasdaq Stock Market, in certain cases subject to certain thresholds and grace periods. If one or more events of default occurs and continues beyond any applicable cure period, SVB may, without notice or demand to the Borrower, terminate its commitment to make further loans and declare all of the obligations of the Borrowers under the SVB Agreement to be immediately due and payable. The Company was in compliance with all covenants as of March 31, 2023. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. On March 14, 2023, Silicon Valley Bridge Bank, N.A., a new bank that is regulated by the Office of the Comptroller of the Currency, announced that it had assumed all loan positions, including as lender, issuing bank, administrative and any other function that was formerly performed by SVB, and that all commitments to advance under existing credit agreements will be honored in accordance with and pursuant to the terms thereof. On March 27, 2023, First Citizens BancShares, Inc. purchased all of the assets and liabilities of Silicon Valley Bridge Bank, N.A. from the FDIC. No amounts had been drawn under the SVB Agreement as of March 31, 2023. 2016 Funding Commitment In June 2017, ISMMS assigned a loan funding commitment from the Connecticut Department of Economic and Community Development (“DECD”) to the Company (as amended, the “DECD Loan Agreement”), to support the Genetic Sequencing Laboratory Project in Branford, Connecticut, with funding based on the achievement of certain project development phases. The DECD Loan Agreement, provides for a total loan commitment of $15.5 million at a fixed annual interest rate of 2.0% for a term of 10 years. The Company is required to make interest-only payments through July 2023 and principal and interest payments commencing in August 2023. The final payment of principal and interest is due in July 2028. However, under the terms of the DECD Loan Agreement, the DECD may grant partial principal loan forgiveness of up to $12.3 million in the aggregate. Such forgiveness is contingent upon the Company achieving job creation and retention milestones and $4.5 million has been forgiven as of March 31, 2023. This commitment is collateralized by providing a security interest in certain machinery and equipment the Company acquired from ISMMS, as defined in a separate security agreement. In January 2023, the Company amended the DECD Loan Agreement, which resulted in the Company agreeing to pay $2.0 million in principal, obtaining $2.8 million in debt forgiveness for achieving its Phase 2 job milestone, and agreeing to two new forgiveness milestone targets for its Phase 3 job milestone (eligible for $2 million in forgiveness) and the final phase job milestone (eligible for $1 million in forgiveness) (the “2022 Amended DECD Loan Agreement”). Upon execution of this amendment in January 2023, the Company paid the $2.0 million in principal and received $2.75 million in debt forgiveness, both of which were classified as current liabilities as of December 31, 2022 and the Company recognized the debt forgiveness as other income in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023. The terms of the 2022 Amended DECD Loan Agreement require the Company to make interest-only payments through July 2024 and principal and interest payments commencing in August 2024 through July 2029 at the same fixed annual interest rate of 2.0%. The outstanding loan balance from the DECD Loan Agreement was $6.3 million as of March 31, 2023. Maturities of Long-Term Debt As of March 31, 2023, long-term debt matures as follows (in thousands): 2023 (remainder of year) $ — 2024 497 2025 1,211 2026 1,234 2027 1,260 Thereafter 2,048 Total maturities of long-term debt 6,250 Less: current portion of long-term debt — Total long-term debt, net of current maturities $ 6,250

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	Leases Lease Accounting The Company enters into contracts in the normal course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception if it conveys the right to control the identified asset for a period of time in exchange for consideration. The Company classifies leases as operating or financing in nature. All lease liabilities are measured at the present value of the associated payments, discounted using the Company’s incremental borrowing rate determined based on the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for similar term and in a similar economic environment on a collateralized basis, unless there is a rate implicit in the lease that is readily determinable. Operating Leases The Company's operating lease arrangements are principally for office space and laboratory facilities. The Company’s headquarter lease was initially entered into via sub-lease agreements with ISMMS and a third party and will expire in 2034. The Company also entered into a separate lease with a third party for space in the same building as its headquarters and that lease expires in 2029. The agreements include escalating rent and rent-free period provisions. Pursuant to the terms of the lease agreement, the Company was required to have issued an irrevocable standby letter of credit to the lessor for $0.9 million, which was included in restricted cash in the condensed consolidated balance sheets as of March 31, 2023 and consolidated balance sheets as of December 31, 2022. In April 2019, the Company entered into a sublease agreement with ISMMS as a sublessee to the ISMMS agreement to the lessor to rent a building to be used for office and laboratory facility (the “Stamford Lease”) for a base term of 325 months, expiring in October 2046. The Company has the option to renew the lease at the end of the initial base term for either one period of 10 years, or two periods of 5 years. There is also an early termination option in which ISMMS may cancel the lease after the 196 th month with cancellation fees. At inception of the Stamford Lease, the value of the land was determined to be more than 25% of the total value and therefore the building is accounted for as a finance lease and the land as an operating lease. In January 2020, the Company entered into a lease agreement which expanded the Company’s existing laboratory facility in Branford, Connecticut. The lease commenced in February 2020 with a 10-year term. The lease includes escalating rent fees over the lease term. In April 2022, the Company acquired an operating lease for office space and laboratory operations in connection with the Acquisition. The lease includes a base term of 9 years remaining from the date of acquisition and an escalating rent provision. In July 2022, the Company executed a lease agreement to extend the lease term of existing office spaces, commencing in September 2022 for a period of 13 months. In March 2023, the Company entered into an agreement with ISMMS to use its commercially reasonable efforts to exercise the early termination option existing in the lease agreement between ISMMS and the lessor. This triggered lease modification accounting to shorten the total lease term, from a total of 23 years remaining to an estimated 13 years remaining, as the Company intends to request the exercise of this option available. The Company is required to make a payment of $8.4 million as an early termination fee if they choose to exercise this option. This modification resulted in an increase in the operating lease liability by $2.0 million and an increase in the finance lease liability by $2.6 million, respectively, as of March 31, 2023, due to reassessment and reapplication of the incremental borrowing rate as of the lease modification date. The Company identified indicators of impairment specifically with the modification of the sublease agreement. As a result, the Company recorded a $1.6 million impairment charge within impairment loss in the Company’s condensed consolidated statements of operations and comprehensive loss for the quarter ended March 31, 2023, of which $0.8 million was allocated to the right-of-use asset associated with the sublease. Finance Leases The Company enters into various finance lease agreements to obtain laboratory equipment that contain bargain purchase commitments at the end of the lease term. The leases are secured by the underlying equipment. As discussed above, the Company also leases a building used for office and laboratory space in which the building is accounted for as a finance lease and the land is as an operating lease. The interest rate initially used for the Stamford Lease was 13.1%, which was modified to 8.5% upon the lease modification explained above. The revised rate was used to measure the operating and finance lease liability. The tables below present financial information associated with the Company’s leases (in thousands). Classification March 31, 2023 December 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 33,235 $ 32,758 Finance lease assets Property and Equipment, net 9,668 8,604 Total lease assets $ 42,903 $ 41,362 Liabilities Current Operating Short-term lease liabilities 2,349 $ 2,409 Finance Short-term lease liabilities 2,850 3,712 Non-current Operating Long-term lease liabilities 45,816 $ 44,468 Finance Long-term lease liabilities 18,067 15,545 Total lease liabilities $ 69,082 $ 66,134 Lease cost Three months ended March 31, 2023 Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,735 $ 1,380 Short-term lease cost 203 169 Variable lease cost 264 127 Total operating lease cost $ 2,202 $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 775 $ 912 Interest on lease liabilities 544 552 Total finance lease cost $ 1,319 $ 1,464 Total lease cost $ 3,521 $ 3,140 Future minimum lease payments under non-cancellable leases as of March 31, 2023 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2023 (remainder of the year) $ 3,005 $ 760 $ 3,765 2024 5,529 4,117 9,646 2025 5,960 2,511 8,471 2026 6,110 2,031 8,141 2027 6,259 2,045 8,304 Thereafter 43,794 25,135 68,929 Total $ 70,657 $ 36,599 $ 107,256 Less: imputed interest $ (22,492) $ (15,682) $ (38,174) Present value of lease liabilities $ 48,165 $ 20,917 $ 69,082 Other information related to leases as of and for the three months ended March 31, 2023 are as follows: March 31, 2023 Weighted-average remaining lease term (years) Operating leases 10.7 Finance leases 11.5 Weighted-average discount rate Operating leases 6.3% Finance leases 10.8% Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $346 Operating cash flows from finance leases $146 Financing cash flows from finance lease $1,046
Leases	Leases Lease Accounting The Company enters into contracts in the normal course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception if it conveys the right to control the identified asset for a period of time in exchange for consideration. The Company classifies leases as operating or financing in nature. All lease liabilities are measured at the present value of the associated payments, discounted using the Company’s incremental borrowing rate determined based on the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for similar term and in a similar economic environment on a collateralized basis, unless there is a rate implicit in the lease that is readily determinable. Operating Leases The Company's operating lease arrangements are principally for office space and laboratory facilities. The Company’s headquarter lease was initially entered into via sub-lease agreements with ISMMS and a third party and will expire in 2034. The Company also entered into a separate lease with a third party for space in the same building as its headquarters and that lease expires in 2029. The agreements include escalating rent and rent-free period provisions. Pursuant to the terms of the lease agreement, the Company was required to have issued an irrevocable standby letter of credit to the lessor for $0.9 million, which was included in restricted cash in the condensed consolidated balance sheets as of March 31, 2023 and consolidated balance sheets as of December 31, 2022. In April 2019, the Company entered into a sublease agreement with ISMMS as a sublessee to the ISMMS agreement to the lessor to rent a building to be used for office and laboratory facility (the “Stamford Lease”) for a base term of 325 months, expiring in October 2046. The Company has the option to renew the lease at the end of the initial base term for either one period of 10 years, or two periods of 5 years. There is also an early termination option in which ISMMS may cancel the lease after the 196 th month with cancellation fees. At inception of the Stamford Lease, the value of the land was determined to be more than 25% of the total value and therefore the building is accounted for as a finance lease and the land as an operating lease. In January 2020, the Company entered into a lease agreement which expanded the Company’s existing laboratory facility in Branford, Connecticut. The lease commenced in February 2020 with a 10-year term. The lease includes escalating rent fees over the lease term. In April 2022, the Company acquired an operating lease for office space and laboratory operations in connection with the Acquisition. The lease includes a base term of 9 years remaining from the date of acquisition and an escalating rent provision. In July 2022, the Company executed a lease agreement to extend the lease term of existing office spaces, commencing in September 2022 for a period of 13 months. In March 2023, the Company entered into an agreement with ISMMS to use its commercially reasonable efforts to exercise the early termination option existing in the lease agreement between ISMMS and the lessor. This triggered lease modification accounting to shorten the total lease term, from a total of 23 years remaining to an estimated 13 years remaining, as the Company intends to request the exercise of this option available. The Company is required to make a payment of $8.4 million as an early termination fee if they choose to exercise this option. This modification resulted in an increase in the operating lease liability by $2.0 million and an increase in the finance lease liability by $2.6 million, respectively, as of March 31, 2023, due to reassessment and reapplication of the incremental borrowing rate as of the lease modification date. The Company identified indicators of impairment specifically with the modification of the sublease agreement. As a result, the Company recorded a $1.6 million impairment charge within impairment loss in the Company’s condensed consolidated statements of operations and comprehensive loss for the quarter ended March 31, 2023, of which $0.8 million was allocated to the right-of-use asset associated with the sublease. Finance Leases The Company enters into various finance lease agreements to obtain laboratory equipment that contain bargain purchase commitments at the end of the lease term. The leases are secured by the underlying equipment. As discussed above, the Company also leases a building used for office and laboratory space in which the building is accounted for as a finance lease and the land is as an operating lease. The interest rate initially used for the Stamford Lease was 13.1%, which was modified to 8.5% upon the lease modification explained above. The revised rate was used to measure the operating and finance lease liability. The tables below present financial information associated with the Company’s leases (in thousands). Classification March 31, 2023 December 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 33,235 $ 32,758 Finance lease assets Property and Equipment, net 9,668 8,604 Total lease assets $ 42,903 $ 41,362 Liabilities Current Operating Short-term lease liabilities 2,349 $ 2,409 Finance Short-term lease liabilities 2,850 3,712 Non-current Operating Long-term lease liabilities 45,816 $ 44,468 Finance Long-term lease liabilities 18,067 15,545 Total lease liabilities $ 69,082 $ 66,134 Lease cost Three months ended March 31, 2023 Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,735 $ 1,380 Short-term lease cost 203 169 Variable lease cost 264 127 Total operating lease cost $ 2,202 $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 775 $ 912 Interest on lease liabilities 544 552 Total finance lease cost $ 1,319 $ 1,464 Total lease cost $ 3,521 $ 3,140 Future minimum lease payments under non-cancellable leases as of March 31, 2023 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2023 (remainder of the year) $ 3,005 $ 760 $ 3,765 2024 5,529 4,117 9,646 2025 5,960 2,511 8,471 2026 6,110 2,031 8,141 2027 6,259 2,045 8,304 Thereafter 43,794 25,135 68,929 Total $ 70,657 $ 36,599 $ 107,256 Less: imputed interest $ (22,492) $ (15,682) $ (38,174) Present value of lease liabilities $ 48,165 $ 20,917 $ 69,082 Other information related to leases as of and for the three months ended March 31, 2023 are as follows: March 31, 2023 Weighted-average remaining lease term (years) Operating leases 10.7 Finance leases 11.5 Weighted-average discount rate Operating leases 6.3% Finance leases 10.8% Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $346 Operating cash flows from finance leases $146 Financing cash flows from finance lease $1,046

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations In the normal course of business, the Company enters into various purchase commitments primarily related to material and service agreements, laboratory supplies and software. As of March 31, 2023, the Company’s total future payments under noncancellable unconditional purchase commitments having a remaining term of over one year were $3.4 million. The Company enters into contracts with suppliers to purchase materials needed for diagnostic testing. These contracts generally do not require multiple-year purchase commitments. Contingencies The Company is a party to various actions and claims arising in the normal course of business. The Company does not believe that the outcome of these matters will have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows. However, no assurance can be given that the final outcome of such proceedings will not materially impact the Company’s condensed consolidated financial condition or results of operations. Except as described below, the Company was not a party to any material legal proceedings as of March 31, 2023, nor is it a party to any material legal proceedings as of the date of issuance of these unaudited condensed consolidated financial statements. On September 7, 2022, a shareholder class action lawsuit was filed in the United States District Court for the District of Connecticut against the Company and certain of the Company’s current and former officers. Following the appointment of a lead plaintiff, an amended complaint was filed on January 30, 2023. As amended, the complaint purports to bring suit on behalf of stockholders who purchased the Company’s publicly traded securities between March 14, 2022 and August 15, 2022. The complaint purports to allege that defendants made false and misleading statements about the Company’s business, operations and prospects in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and seeks unspecified compensatory damages, fees and costs. The Company believes the allegations and claims made in the complaint are without merit. On February 7, 2023, a stockholder commenced a lawsuit in the Delaware Court of Chancery. The suit is brought as a class action on behalf of stockholders of CMLS who did not redeem their shares in connection with the Business Combination. The suit names as defendants all directors of CMLS at the time of the transaction, including directors who continue to serve on the Company’s board of directors, as well as CMLS Holdings LLC, the Former Sponsor. The Company is not named as a defendant. The complaint alleges that the July 2, 2021 proxy statement mailed to CMLS stockholders in connection with the transaction contained false and misleading statements, and purports to assert a claim of breach of fiduciary duty against all individual defendants, and a similar claim against the Former Sponsor and certain individuals for breach of fiduciary duty as control persons. The suit seeks to recover unspecified damages on behalf of the alleged class, among other relief. The Company believes the allegations and claims made in the complaint are without

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Incentive Plans The Company’s 2017 Equity Incentive Plan (the “2017 Plan”), as amended in February 2018, allowed the grant of options, restricted stock awards, stock appreciation rights and restricted stock units. No options granted under the 2017 Plan are exercisable after 10 years from the date of grant, and option awards generally vest over a four-year period. The 2017 Plan was terminated in connection with the adoption of the Company's 2021 Equity Incentive Plan (the “2021 Plan”). Any awards granted under the 2017 Plan that remained outstanding as of the Closing Date and were converted into awards with respect to the Company’s Class A common stock in connection with the consummation of the Business Combination continue to be subject to the terms of the 2017 Plan and applicable award agreements, except for a modification of the repurchase provision, which is discussed further below. On July 22, 2021, in connection with the Business Combination, the 2021 Plan became effective and 991,970 authorized shares of Class A common stock were reserved for issuance thereunder. The 2021 Plan is administered by the Compensation Committee of the Company’s Board of Directors, including determination of the vesting, exercisability and payment of the awards to be granted under the 2021 Plan. No awards granted under the 2021 Plan are exercisable after 10 years from the date of grant, and the awards granted under the 2021 Plan generally vest over a four-year period on a graded vesting basis. On April 14, 2023, the stockholders of the Company approved an amendment and restatement to the 2021 Plan to increase the aggregate number of shares of the Company’s Class A common stock authorized for issuance under the 2021 Plan by 787,879 shares and implement certain other clarifying changes. Employee Stock Purchase Plan The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) became effective in connection with the Business Combination. The 2021 ESPP authorizes the issuance of shares of Class A common stock pursuant to purchase rights granted to employees. On each January 1 of each of 2022 through 2031, the aggregate number of shares of Class A common stock reserved for issuance under the 2021 Plan may be increased automatically by the number of shares equal to one percent (1%) of the total number of shares of all classes of common stock issued and outstanding immediately preceding December 31. The Company did not make any grants of purchase rights under the 2021 ESPP during the quarter ended March 31, 2023. A total of 336,816 shares of Class A common stock have been reserved for future issuance under the 2021 ESPP. Stock Option Activity Under the 2017 Plan, the Company had a call option to repurchase awards for cash from the plan participants upon termination of the participant’s employment or consulting agreement (the “2017 Plan Call Option”). The options granted under the 2017 plan were accounted for as liability awards due to the 2017 Plan Call Option. The Company had a history of repurchase practice and the intention to repurchase the vested options. Therefore, the fair value of the liability awards was remeasured at each reporting period until the stockholder bears the risks and rewards of equity ownership for a reasonable period of time, which the Company concludes is at least six months. Upon consummation of the Business Combination, the Company’s Board of Directors waived the Company’s right under the 2017 Plan Call Option to repurchase awards for cash from the plan participants upon termination of the participant’s employment or consulting agreement. As such, the Company modified the liability awards to equity awards and reclassified the modification date fair value of the awards to stockholders’ equity in the condensed consolidated financial statements as of July 22, 2021. All stock options granted under the 2021 Plan are accounted for as equity awards. The following summarizes the stock option activity during the quarter ended March 31, 2023: Stock Options Outstanding Weighted Average Exercise Price Balance at December 31, 2022 798,873 $ 49.83 Options granted — — Options exercised (50,444) 5.05 Options forfeited or canceled (38,829) 66.12 Balance at March 31, 2023 709,600 $ 52.09 Options exercisable at March 31, 2023 395,403 $ 38.04 As of March 31, 2023 , unrecognized stock-based compensation cost related to the unvested portion of the Company’s stock options was $8.8 million, which is expected to be recognized on a graded-vesting basis over a weighted-average period of 1.7 years. There were no stock options awarded during the three month period ended March 31, 2023. The fair value of the stock option awards for the period ended March 31, 2022 were estimated using the Black-Scholes option pricing model with the following assumptions: Three months ended March 31, 2022 Expected volatility 65.20% - 67.60% Expected term (in years) 5.48-6.06 Risk-free interest rate 1.65%-1.70% Dividend yield — Fair value of Class A common stock $108.57-$113.85 The Company estimated a volatility factor for the Company’s options based on analysis of historical share prices of a peer group of public companies, the historical share prices of the Company, and the implied volatility of the Company’s call options. The Company estimated the expected term of options granted using the “simplified method,” which is the mid-point between the vesting date and the ending date of the contractual term. The Company did not rely on the historical holding periods of the Company’s options due to the limited availability of exercise data. The Company used a risk-free interest rate based on the U.S. Treasury yield curve in effect for bonds with maturities consistent with the expected term of the option. Restricted Stock Units (RSUs) The Company issued time-based RSUs to employees under the 2021 Plan. The RSUs automatically convert to shares of Class A common stock on a one-for-one basis as the awards vest. The Company measures the value of RSUs at fair value based on the closing price of the underlying Class A common stock on the grant date. The RSUs granted generally vest over a four year vesting period from the grant date, however, certain grants include vesting term that begins vesting 12 months from the grant date. The following table summarizes the activity related to the Company's time-based RSUs: Restricted Stock Units Outstanding Weighted Average Grant Date Fair Value Per Unit Balance at December 31, 2022 855,061 $ 77.88 Restricted Stock Units granted 560,725 $ 10.78 Restricted Stock Units vested (54,175) $ 102.45 Restricted Stock Units forfeited (97,621) $ 138.91 Balance at March 31, 2023 1,263,990 $ 41.56 Additionally, the Company issued 18,794 RSUs subject to both service and performance based vesting conditions to the Executive Chairman of the Company. The grant date was established during the first quarter period and vesting of the RSUs will be based on the achievement of performance goals established for calendar year 2023. Earn-out RSUs The grant date fair value determined for Triggering Event I, II and III was $60.06, $45.87 and $31.02 per unit, respectively. Any re-allocated RSUs due to the Legacy Sema4 option holders’ forfeiture activities during the three months ended March 31, 2023 were accounted for as new grants and the fair value determined for Triggering Event I, II and III was $0.00, $0.00 and $0.00 per unit, respectively. Based on the grant date fair value, the Company recorded a reversal of stock-based compensation of $0.8 million due to the Legacy Sema4 option holders’ forfeiture activities. The Company recognizes the stock-compensation cost over the longer of the derived service period or service period. Stock Appreciation Rights (SAR) Activity The Company historically granted SAR to one employee and one consultant with exercise condition of a liquidation event. As a result of the Business Combination, settlement of the outstanding vested SARs in exchange for a cash payment and to cancel the outstanding unvested SARs was agreed upon and an expense of $3.8 million related to the vested SAR was recognized by the Company. There were no outstanding SARs as of March 31, 2023. During the three months ended March 31, 2023, the Company recorded a reversal of stock-based compensation of $8.1 million due to forfeiture activities upon employee terminations. Stock-based compensation expense for all awards granted and outstanding is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2023 2022 Cost of services $ (1,666) $ 1,381 Research and development 943 4,341 Selling and marketing 63 2,825 General and administrative 708 9,012 Total stock-based compensation expense $ 48 $ 17,559

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax benefit for the three months ended March 31, 2023 and 2022 was $0.1 million and zero, respectively. Income taxes for these periods are recorded at the Company’s estimated annual effective income tax rate, subject to adjustments for discrete events should they occur. The Company’s estimated annual effective tax rate was 0.30% for the three months ended March 31, 2023. The difference between the Company’s effective tax rates in 2022 and 2021 compared to the U.S. statutory tax rate of 21% is primarily due to changes in valuation allowances associated with the Company’s assessment of the likelihood of the

Net Income (loss) per Share

Net Income (loss) per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Income (loss) per Share	Net Income (loss) per Share Basic and diluted loss per share attributable to common stockholders was calculated as follows (amounts in thousands, except for share and per share amounts): Three months ended March 31, 2023 2022 Numerator: Net (loss) income attributable to common stockholders $ (60,989) $ (76,896) Denominator: Denominator for basic and diluted earnings per share-weighted-average common shares 20,061,945 7,405,113 Basic and diluted earnings (loss) income per share $ (3.04) $ (10.38) As a result of the Reverse Stock Split, the Company has retroactively adjusted the weighted-average number of shares of common stock outstanding prior to the Reverse Stock Split by a ratio of 1-for-33 to determine the number of shares of common stock into which they converted. The following tables summarize the outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been anti-dilutive: As of March 31, 2023 2022 Outstanding options and RSUs to purchase Class A common stock 1,973,590 1,242,790 Outstanding warrants 666,515 666,515 Outstanding earn-out shares 554,799 503,367 Outstanding earn-out RSUs 21,613 73,045 Total 3,216,517 2,485,717

Restructuring Costs

Restructuring Costs	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring Costs	Restructuring CostsDuring the three months ended March 31, 2023, the Company’s strategic realignment was completed by exiting its reproductive and women’s health testing business, which included carrier screening, noninvasive prenatal, and other ancillary reproductive testing offerings. The Company ceased accepting samples for these tests on December 14, 2022 and notified its customers impacted by the decision immediately. As a result, the Company eliminated approximately 500 positions, and ceased operations at its Stamford, CT laboratory. When combined with the Company’s prior reductions in workforce during 2022, the exit resulted in the elimination of approximately 32.5% of the Company’s workforce as of March 31, 2023. The table below provides certain information concerning restructuring activity during the three months ended March 31, 2023: Reserve Balance at December 31, 2022 Charged to Costs and Expenses Payments and Other Reserve Balance at March 31, 2023 Severance $ 4,770 $ 308 $ (3,700) $ 1,378 Others $ 253 $ 18 $ (254) $ 17 Total 5,023 $ 326 $ (3,954) $ 1,395 The Company may incur additional expenses not currently contemplated due to events associated with the reduction in workforce. The charges that the Company expects to incur in connection with the reduction in workforce are estimates and subject to a number of assumptions, and actual results may differ materially.

Supplemental Financial Informat

Supplemental Financial Information	3 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Supplemental Financial Information	Supplemental Financial Information Accounts payable and accrued expenses consisted of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Accounts payable $ 36,918 $ 46,017 Accrued purchases 27,570 20,314 Reserves for refunds to insurance carriers (1) 5,000 17,001 Other 401 1,546 Total $ 69,889 $ 84,878 Other current liabilities consisted of the following (in thousands): As of March 31, 2022 As of December 31, 2022 Accrued bonus $ 3,571 $ 8,429 Accrued payroll 754 3,905 Accrued benefits 4,104 1,529 Accrued commissions 958 1,656 Accrued severance 1,378 4,770 Current portion of long-term debt — 4,750 Indemnification liabilities 12,144 13,470 Current portion of the contingent consideration liabilities 8,449 6,019 Other 8,271 5,177 Total $ 39,629 $ 49,705

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting The Company’s business is aligned with how the chief operating decision maker (“CODM”) reviews performance and makes decisions in managing the Company. As of March 31, 2023, the Company has identified two reportable segments: (i) GeneDx inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs and (ii) Legacy Sema4 diagnostics. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent data and information services. The Legacy Sema4 diagnostics segment provided reproductive and women’s health and somatic oncology diagnostic testing and screening products. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on revenue and adjusted gross margin. Prior to the Acquisition, the Company had one segment which is characterized as “Legacy Sema4” in the table below. Prior to the date of the Acquisition, consolidated results were the same as the results of this segment and therefore the results for the first quarter of 2022 has not been presented below. (in thousands) GeneDx Legacy Sema4 Total Three Months Ended March 31, 2023: Revenue $ 40,693 $ 2,446 $ 43,139 Adjusted cost of services 26,826 2,080 28,906 Adjusted gross margin (loss) 13,867 366 14,233 Reconciliations: Depreciation and amortization 476 113 589 Stock-based compensation 305 (1,971) (1,666) Restructuring charges 43 31 74 Gross margin (loss) 13,043 2,193 15,236 The following table summarizes the Company’s disaggregated revenue (in thousands): Three Months Ended March 31, 2023 GeneDx Legacy Sema4 Consolidated Diagnostic test revenue: Patients with third-party insurance $ 22,878 $ 2,451 $ 25,329 Institutional customers 16,060 — $ 16,060 Self-pay patients 466 (5) 461 Total diagnostic test revenue 39,404 2,446 41,850 Other revenue 1,289 — 1,289 Total $ 40,693 $ 2,446 $ 43,139 Management manages assets on a total company basis, not by reporting segment. The CODM does not regularly review any asset information by reporting segment and, accordingly, the Company does not report asset information by reporting segment.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible AssetsAs discussed in Note 3, Business Combinations, upon the Acquisition of Legacy GeneDx in April 2022, the Company recorded initial goodwill of $185.9 million through its preliminary purchase allocation. The purchase price allocation for acquired businesses may be modified for up to one year from the date of acquisition if additional facts or circumstances lead to changes in the Company’s preliminary purchase accounting estimates. The Company is substantially complete with measurement period adjustments as of March 31, 2023. The changes in the carrying amounts of goodwill were as follows (in thousands): March 31, 2023 Balance as of December 31, 2022 $ — Additions — Measurement period adjustments 478 Impairment charges (478) Balance as of March 31, 2023 $ — The following table reflects the fair values and remaining useful lives of the acquired intangible assets identified based on the Company’s preliminary purchase accounting assessments as of March 31, 2023 (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted-Average Tradenames and trademarks $ 50,000 $ 2,864 $ 47,136 15.1 Developed technology 48,000 5,500 42,500 7.1 Customer relationships 98,000 4,492 93,508 19.1 $ 196,000 $ 12,856 $ 183,144 Amortization expense for tradenames and trademarks and developed technology of $2.3 million was recorded in general and administrative for the three months ended March 31, 2023 within the condensed consolidated statements of operations and comprehensive loss. Amortization expense for customer relationships of $1.2 million was recorded in selling and marketing for the three months ended March 31, 2023 within the condensed consolidated statements of operations and comprehensive loss. The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of March 31, 2023 (in thousands): 2023 (remainder of the year) $ 10,519 2024 14,025 2025 14,025 2026 14,025 2027 14,025 Thereafter 116,525 Total estimated future amortization expense $ 183,144

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Reverse Stock Split The stockholders of the Company approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of the issued and outstanding shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), at a ratio ranging from 1-for-10 and 1-for-50, with the exact ratio to be set within that range by the Company’s board of directors (the “Board”). On April 24, 2023, the Board approved the reverse stock split at a ratio of 1-for-33. On April 28, 2023, the Company filed a Certificate of Amendment (the “Reverse Stock Split Certificate of Amendment”) to the Charter with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of May 4, 2023. As a result of the Reverse Stock Split, every 33 shares of Class A Common Stock were automatically reclassified and converted into one issued and outstanding share of Class A Common Stock. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share. The par value of Class A common Stock remained unchanged at $0.0001 per share. Closing of Additional Shares in Registered Direct Offering On April 17, 2023, following the Company’s receipt of stockholder approval for the issuance, the Company issued the remaining 676,868 shares of the Company’s Class A common stock to Corvex Select Equity Master Fund LP, Corvex Master Fund LP and Corvex Dynamic Equity Select Master Fund LP in its previously announced registered direct offering for gross proceeds of approximately $7.6 million . First Milestone Payment in Connection With the Acquisition On April 14, 2023, as a result of the first Milestone Payment becoming due and payable in full, the Company issued 701,460 shares of the Company’s Class A common stock to OPKO pursuant to the Acquisition Merger Agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. As such, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto as of and for the years ended December 31, 2022, 2021 and 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 21, 2022 filed on March 16, 2023 (the “Annual Report”). The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to state fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results of operations or cash flows for a full year or any subsequent interim period. The Company’s historical financial information includes costs of certain services historically provided by Icahn School of Medicine at Mount Sinai (“ISMMS”) pursuant to a Transition Services Agreement (“TSA”) and service agreements. See Note 7, “Related Party Transactions”. Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the date of filing of this Quarterly Report on Form 10-Q.
Reverse Stock Split	Reverse Stock Split On May 4, 2023, at the commencement of trading, the Company effected a 1-for-33 reverse stock split. Accordingly, all share and per share amounts for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split.
Reclassifications	ReclassificationsCertain reclassifications have been made to the prior year unaudited condensed consolidated financial statements in order to conform to the current year’s presentation.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the capitalization of software costs, the valuation of stock-based awards, inventory, earn-out contingent liabilities and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The majority of the Company’s cash, cash equivalents and restricted cash are uninsured with account balances in excess of the Federal Deposit Insurance Company limits. As of March 31, 2023, 100% of the Company’s cash, cash equivalents and marketable securities was held in high-quality institutions designated as systematically important financial institutions. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds. Carrying values of cash equivalents approximate fair value due to the short-term nature of these instruments.
Accounts Receivable	Accounts Receivable Accounts receivable consists of amounts due from customers and third-party payors for services performed and reflect the consideration to which the Company expects to be entitled in exchange for providing those services. Accounts receivable are estimated and recorded in the period the related revenue is recorded. The accounts receivable balance as of March 31, 2023 and December 31, 2022 included $2.9 million and $1.5 million, respectively, of unbilled receivables. During the quarter ended March 31, 2023, the Company did not record provisions for doubtful accounts. The Company did not write off any accounts receivable balances for the period.
Inventory, net	Inventory, netInventory, net, which primarily consists of finished goods such as testing supplies and reagents, is capitalized when purchased and expensed when used in performing services. Inventory is stated at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The Company periodically performs obsolescence assessments and writes off any inventory that is no longer usable. Any write-down of inventory to net realizable value creates a new cost basis.
Fair Value Measurements	Fair Value Measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. The following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market: Level 1 : Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 : Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active or model-derived valuations whose significant inputs are observable. Level 3 : Unobservable inputs that are significant to the measurement of fair value but are supported by little to no market data. The Company’s financial assets and liabilities consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short-term nature of these accounts. The Company’s loan from the Connecticut Department of Economic and Community Development is classified within level 2 of the fair value hierarchy. As of March 31, 2023, this loan is recorded at its carrying value of $6.3 million in the consolidated balance sheet. The fair value of the loan is $5.1 million, which is estimated based on discounted cash flows using the yields of similar debt instruments of other companies with similar credit profiles.
Segment Information	Segment Information Historically, the Company operated in one segment. During 2022, in connection with the Acquisition, the change in Chief Operating Decision Maker (“CODM”), and the announced exit from the majority of the Legacy Sema4 diagnostics operations, the Company’s CODM began to evaluate the Company’s business separately for GeneDx, inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs and corporate support costs, and the existing Legacy Sema4 diagnostics business during the fourth quarter of 2022. As a result, the Company has concluded that two reportable segments exist and have been presented as such for the first quarter of 2023. The majority of the Company’s operations for the first quarter of 2022 are included in the Legacy Sema4 segment and the majority of the GeneDx segment for 2022 was resultant from the Acquisition in 2022, and thus did not exist within the Company’s condensed consolidated results for the first quarter of 2022. As a result, the Company has not presented segments for the first quarter of 2022. See Note 16, “ Segment Reporting ”, for the first quarter of 2023 segment disclosures.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The new credit losses standard changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, contract assets recognized as a result of applying ASC 606, loans and certain other instruments, entities will be required to use a new forward looking “expected loss” model that generally will result in earlier recognition of credit losses than under today’s incurred loss model. The Company adopted ASU 2016-13 effective January 1, 2023 and the adoption did not have material impact in the condensed consolidated statements of operations and comprehensive loss. Recently Issued Accounting Pronouncements Not Yet Adopted The Company has reviewed the recently issued Accounting Standards Update accounting pronouncements and does not believe that the adoption of any such pronouncements will have a material impact on its financial statements or related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Revenue and Accounts Receivable Concentration Percentages	For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows: Revenue Accounts Receivable Three months ended March 31, As of March 31, As of December 31, 2023 2022 2023 2022 Payor A * 24% * * Payor B (1) 15% * * 14% Payor D * 10% * * Payor E 24% * 15% 14% *less than 10% __________________ (1) This payor includes multiple individual plans and the Company calculates and presents the aggregated value from all plans, which is consistent with the Company’s portfolio approach used in accounting for diagnostic test revenue.
Schedule of Reconciliation of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): As of March 31, 2023 As of December 31, 2022 Cash and cash equivalents $ 201,895 $ 123,933 Restricted cash 13,044 14,370 Total $ 214,939 $ 138,303
Schedule of Reconciliation of Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): As of March 31, 2023 As of December 31, 2022 Cash and cash equivalents $ 201,895 $ 123,933 Restricted cash 13,044 14,370 Total $ 214,939 $ 138,303

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the net purchase price and the fair values of the assets and liabilities of Legacy GeneDx on a preliminary basis (in thousands): Cash and cash equivalents $ — Accounts receivables 21,651 Inventory 6,210 Prepaid expenses 4,671 Other current assets 320 Property and equipment 29,509 Other non-current assets 6,464 Trade names and trademarks 50,000 Developed technology 48,000 Customer relationships 98,000 Accounts payable and accrued expenses (12,862) Other current liabilities (15,781) Deferred tax liabilities (51,779) Long-term lease liabilities (5,798) Fair value of net assets acquired 178,605 Goodwill (1) 185,871 Aggregate purchase price $ 364,476 (1) Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. See Note 17, “Goodwill and Intangible Assets” for more detail.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Disaggregated by Type of Customer	The following table summarizes the Company’s disaggregated revenue by payor category (in thousands): Three months ended March 31, 2023 2022 Diagnostic test revenue Patients with third-party insurance $ 25,329 $ 47,462 Institutional customers 16,060 4,031 Self-pay patients 461 1,002 Total diagnostic test revenue 41,850 52,495 Other revenue 1,289 1,446 Total $ 43,139 $ 53,941

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value on a Recurring Basis	The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands): As of March 31, 2023 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 45,069 $ 45,069 $ — $ — Total financial assets $ 45,069 $ 45,069 $ — $ — Financial Liabilities: Public warrant liability $ 295 $ 295 $ — $ — Private warrant liability 145 — 145 — DECD loan 5,110 — 5,110 — Contingent consideration based on milestone achievement 11,049 — — 11,049 Total financial liabilities $ 16,599 $ 295 $ 5,255 $ 11,049 As of December 31, 2022 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 16,901 $ 16,901 $ — $ — Total financial assets $ 16,901 $ 16,901 $ — $ — Financial Liabilities: Public warrant liability $ 280 $ 280 $ — $ — Private warrant liability 138 — 138 — DECD loan 4,904 — 4,904 — Contingent consideration based on milestone achievement 7,619 — — 7,619 Total financial liabilities $ 12,941 $ 280 $ 5,042 $ 7,619
Schedule of Utilized in Determining Valuation	The key assumptions utilized in determining the Earn-out Shares valuation as of March 31, 2023 and December 31, 2022 were as follows: March 31, 2023 December 31, 2022 Stock price $12.21 $8.58 Expected volatility 120.0% 107.5% Expected term (in years) 0.3 0.6 Risk-free interest rate 4.87% 4.76%

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment and Depreciation and Amortization Expense	Property and equipment, net consisted of the following (in thousands): As of March 31, As of December 31, Laboratory equipment $ 42,370 $ 41,255 Equipment under finance leases 21,384 21,384 Leasehold improvements 35,560 35,561 Capitalized software 32,171 32,171 Building under finance lease 8,059 6,276 Construction in-progress 3,533 3,386 Computer equipment 9,185 9,177 Furniture, fixtures and other equipment 3,777 3,777 Total property and equipment 156,039 152,987 Less: accumulated depreciation and amortization (106,531) (101,460) Property and equipment, net $ 49,508 $ 51,527 Depreciation and amortization expense is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2023 2022 Cost of services $ 589 $ 2,816 Research and development 852 1,849 Selling and marketing 2 1 General and administrative 3,687 1,137 Total depreciation and amortization expenses $ 5,130 $ 5,803

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Expenses	Total related party costs are included within cost of services and related party expenses in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2023 2022 Cost of services $ 815 $ 1,056 Related party expenses 1,747 1,284 Total related party costs $ 2,562 $ 2,340

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Maturities	As of March 31, 2023, long-term debt matures as follows (in thousands): 2023 (remainder of year) $ — 2024 497 2025 1,211 2026 1,234 2027 1,260 Thereafter 2,048 Total maturities of long-term debt 6,250 Less: current portion of long-term debt — Total long-term debt, net of current maturities $ 6,250

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of Lease, Cost	The tables below present financial information associated with the Company’s leases (in thousands). Classification March 31, 2023 December 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 33,235 $ 32,758 Finance lease assets Property and Equipment, net 9,668 8,604 Total lease assets $ 42,903 $ 41,362 Liabilities Current Operating Short-term lease liabilities 2,349 $ 2,409 Finance Short-term lease liabilities 2,850 3,712 Non-current Operating Long-term lease liabilities 45,816 $ 44,468 Finance Long-term lease liabilities 18,067 15,545 Total lease liabilities $ 69,082 $ 66,134 Lease cost Three months ended March 31, 2023 Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,735 $ 1,380 Short-term lease cost 203 169 Variable lease cost 264 127 Total operating lease cost $ 2,202 $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 775 $ 912 Interest on lease liabilities 544 552 Total finance lease cost $ 1,319 $ 1,464 Total lease cost $ 3,521 $ 3,140 March 31, 2023 Weighted-average remaining lease term (years) Operating leases 10.7 Finance leases 11.5 Weighted-average discount rate Operating leases 6.3% Finance leases 10.8% Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $346 Operating cash flows from finance leases $146 Financing cash flows from finance lease $1,046
Schedule of Assets and Liabilities, Lessee	The tables below present financial information associated with the Company’s leases (in thousands). Classification March 31, 2023 December 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 33,235 $ 32,758 Finance lease assets Property and Equipment, net 9,668 8,604 Total lease assets $ 42,903 $ 41,362 Liabilities Current Operating Short-term lease liabilities 2,349 $ 2,409 Finance Short-term lease liabilities 2,850 3,712 Non-current Operating Long-term lease liabilities 45,816 $ 44,468 Finance Long-term lease liabilities 18,067 15,545 Total lease liabilities $ 69,082 $ 66,134 Lease cost Three months ended March 31, 2023 Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,735 $ 1,380 Short-term lease cost 203 169 Variable lease cost 264 127 Total operating lease cost $ 2,202 $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 775 $ 912 Interest on lease liabilities 544 552 Total finance lease cost $ 1,319 $ 1,464 Total lease cost $ 3,521 $ 3,140
Schedule of Finance Lease, Liability, Fiscal Year Maturity	Future minimum lease payments under non-cancellable leases as of March 31, 2023 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2023 (remainder of the year) $ 3,005 $ 760 $ 3,765 2024 5,529 4,117 9,646 2025 5,960 2,511 8,471 2026 6,110 2,031 8,141 2027 6,259 2,045 8,304 Thereafter 43,794 25,135 68,929 Total $ 70,657 $ 36,599 $ 107,256 Less: imputed interest $ (22,492) $ (15,682) $ (38,174) Present value of lease liabilities $ 48,165 $ 20,917 $ 69,082
Schedule of Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments under non-cancellable leases as of March 31, 2023 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2023 (remainder of the year) $ 3,005 $ 760 $ 3,765 2024 5,529 4,117 9,646 2025 5,960 2,511 8,471 2026 6,110 2,031 8,141 2027 6,259 2,045 8,304 Thereafter 43,794 25,135 68,929 Total $ 70,657 $ 36,599 $ 107,256 Less: imputed interest $ (22,492) $ (15,682) $ (38,174) Present value of lease liabilities $ 48,165 $ 20,917 $ 69,082

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following summarizes the stock option activity during the quarter ended March 31, 2023: Stock Options Outstanding Weighted Average Exercise Price Balance at December 31, 2022 798,873 $ 49.83 Options granted — — Options exercised (50,444) 5.05 Options forfeited or canceled (38,829) 66.12 Balance at March 31, 2023 709,600 $ 52.09 Options exercisable at March 31, 2023 395,403 $ 38.04
Schedule of Valuation Assumptions	There were no stock options awarded during the three month period ended March 31, 2023. The fair value of the stock option awards for the period ended March 31, 2022 were estimated using the Black-Scholes option pricing model with the following assumptions: Three months ended March 31, 2022 Expected volatility 65.20% - 67.60% Expected term (in years) 5.48-6.06 Risk-free interest rate 1.65%-1.70% Dividend yield — Fair value of Class A common stock $108.57-$113.85
Schedule of Restricted Stock Units Activity	The following table summarizes the activity related to the Company's time-based RSUs: Restricted Stock Units Outstanding Weighted Average Grant Date Fair Value Per Unit Balance at December 31, 2022 855,061 $ 77.88 Restricted Stock Units granted 560,725 $ 10.78 Restricted Stock Units vested (54,175) $ 102.45 Restricted Stock Units forfeited (97,621) $ 138.91 Balance at March 31, 2023 1,263,990 $ 41.56
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense for all awards granted and outstanding is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2023 2022 Cost of services $ (1,666) $ 1,381 Research and development 943 4,341 Selling and marketing 63 2,825 General and administrative 708 9,012 Total stock-based compensation expense $ 48 $ 17,559

Net Income (loss) per Share (Ta

Net Income (loss) per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	Basic and diluted loss per share attributable to common stockholders was calculated as follows (amounts in thousands, except for share and per share amounts): Three months ended March 31, 2023 2022 Numerator: Net (loss) income attributable to common stockholders $ (60,989) $ (76,896) Denominator: Denominator for basic and diluted earnings per share-weighted-average common shares 20,061,945 7,405,113 Basic and diluted earnings (loss) income per share $ (3.04) $ (10.38)
Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share	The following tables summarize the outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been anti-dilutive: As of March 31, 2023 2022 Outstanding options and RSUs to purchase Class A common stock 1,973,590 1,242,790 Outstanding warrants 666,515 666,515 Outstanding earn-out shares 554,799 503,367 Outstanding earn-out RSUs 21,613 73,045 Total 3,216,517 2,485,717

Restructuring Costs (Tables)

Restructuring Costs (Tables)	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Cost	The table below provides certain information concerning restructuring activity during the three months ended March 31, 2023: Reserve Balance at December 31, 2022 Charged to Costs and Expenses Payments and Other Reserve Balance at March 31, 2023 Severance $ 4,770 $ 308 $ (3,700) $ 1,378 Others $ 253 $ 18 $ (254) $ 17 Total 5,023 $ 326 $ (3,954) $ 1,395

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	3 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accounts payable and accrued expenses consisted of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Accounts payable $ 36,918 $ 46,017 Accrued purchases 27,570 20,314 Reserves for refunds to insurance carriers (1) 5,000 17,001 Other 401 1,546 Total $ 69,889 $ 84,878
Schedule of Other Current Liabilities	Other current liabilities consisted of the following (in thousands): As of March 31, 2022 As of December 31, 2022 Accrued bonus $ 3,571 $ 8,429 Accrued payroll 754 3,905 Accrued benefits 4,104 1,529 Accrued commissions 958 1,656 Accrued severance 1,378 4,770 Current portion of long-term debt — 4,750 Indemnification liabilities 12,144 13,470 Current portion of the contingent consideration liabilities 8,449 6,019 Other 8,271 5,177 Total $ 39,629 $ 49,705

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The CODM evaluates segment performance based on revenue and adjusted gross margin. Prior to the Acquisition, the Company had one segment which is characterized as “Legacy Sema4” in the table below. Prior to the date of the Acquisition, consolidated results were the same as the results of this segment and therefore the results for the first quarter of 2022 has not been presented below. (in thousands) GeneDx Legacy Sema4 Total Three Months Ended March 31, 2023: Revenue $ 40,693 $ 2,446 $ 43,139 Adjusted cost of services 26,826 2,080 28,906 Adjusted gross margin (loss) 13,867 366 14,233 Reconciliations: Depreciation and amortization 476 113 589 Stock-based compensation 305 (1,971) (1,666) Restructuring charges 43 31 74 Gross margin (loss) 13,043 2,193 15,236 The following table summarizes the Company’s disaggregated revenue (in thousands): Three Months Ended March 31, 2023 GeneDx Legacy Sema4 Consolidated Diagnostic test revenue: Patients with third-party insurance $ 22,878 $ 2,451 $ 25,329 Institutional customers 16,060 — $ 16,060 Self-pay patients 466 (5) 461 Total diagnostic test revenue 39,404 2,446 41,850 Other revenue 1,289 — 1,289 Total $ 40,693 $ 2,446 $ 43,139

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amounts of goodwill were as follows (in thousands): March 31, 2023 Balance as of December 31, 2022 $ — Additions — Measurement period adjustments 478 Impairment charges (478) Balance as of March 31, 2023 $ —
Schedule of Acquired Intangible Assets	The following table reflects the fair values and remaining useful lives of the acquired intangible assets identified based on the Company’s preliminary purchase accounting assessments as of March 31, 2023 (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted-Average Tradenames and trademarks $ 50,000 $ 2,864 $ 47,136 15.1 Developed technology 48,000 5,500 42,500 7.1 Customer relationships 98,000 4,492 93,508 19.1 $ 196,000 $ 12,856 $ 183,144
Schedule of Future Amortization Expense	The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of March 31, 2023 (in thousands): 2023 (remainder of the year) $ 10,519 2024 14,025 2025 14,025 2026 14,025 2027 14,025 Thereafter 116,525 Total estimated future amortization expense $ 183,144

Organization and Description _2

Organization and Description of Business (Details)		3 Months Ended
	May 04, 2023	Mar. 31, 2023	Apr. 29, 2022
Organization and Description of Business [Line Items]
Reverse stock split, conversion ratio		0.03
Subsequent Event
Organization and Description of Business [Line Items]
Reverse stock split, conversion ratio	0.030
Legacy GeneDx | Gene D X Holding2 Inc
Organization and Description of Business [Line Items]
Ownership percentage			100%
Affiliated Entities
Organization and Description of Business [Line Items]
Conversion ratio		4

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	May 04, 2023	Apr. 14, 2023 shares	Apr. 29, 2022 $ / shares shares	Dec. 09, 2021 d $ / shares shares	Apr. 30, 2023 USD ($) shares	Mar. 31, 2023 USD ($) segment d $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) segment	Sep. 30, 2022 USD ($)	Mar. 31, 2023 USD ($) segment $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 segment shares	Sep. 04, 2021 $ / shares	Jul. 22, 2021 shares
Property, Plant and Equipment [Line Items]
Reverse stock split, conversion ratio						0.03
Restricted cash						$ 13,044		$ 14,370		$ 13,044	$ 14,370
Unbilled receivables						2,900		1,500		2,900	1,500
Provision for doubtful accounts						0
Write off of accounts receivable						0
Outstanding loan balance						$ 6,250				$ 6,250
Purchase of warrants (in shares) | shares												666,515		666,516
Expected term (in years)						5 years				5 years
Target share price of warrants or rights for redemption (in dollars per share) | $ / shares						$ 594				$ 594
Redemption price per warrant (in dollars per share) | $ / shares						$ 0.33
Number of days for written notice of redemption | d						30
Minimum number of trading days | d						30
Earn-out contingent liability						$ 0		$ 0		$ 0	0
Total stock-based compensation expense						$ 48	$ 17,559
Number of operating segments | segment												1
Number of reportable segments | segment						2		2		1
Connecticut Department Of Economic And Community Development
Property, Plant and Equipment [Line Items]
Outstanding loan balance						$ 6,300				$ 6,300
Long-term debt, fair value						$ 5,100				$ 5,100
Subsequent Event
Property, Plant and Equipment [Line Items]
Reverse stock split, conversion ratio	0.030
Restricted Stock Units (RSUs)
Property, Plant and Equipment [Line Items]
Restricted stock units granted (in shares) | shares						560,725
Class A Common Stock Equals or Exceeds, $18.00
Property, Plant and Equipment [Line Items]
Minimum number of trading days | d						20
Consecutive trading day threshold | d						30
Class A common stock
Property, Plant and Equipment [Line Items]
Purchase of aggregate private placement warrants (shares) | shares						1				1
Warrant exercise price (in dollars per share) | $ / shares													$ 379.50
Target share price of warrants or rights for redemption (in dollars per share) | $ / shares						$ 330				$ 330
Minimum number of trading days | d						20
Consecutive trading day threshold | d						30
Common stock threshold, number of trading days before notice of redemption | d						3
Redemption on warrant holders (in dollars per share) | $ / shares						$ 594
Class A common stock | Minimum
Property, Plant and Equipment [Line Items]
Reverse stock split, conversion ratio						0.10
Class A common stock | Maximum
Property, Plant and Equipment [Line Items]
Reverse stock split, conversion ratio						0.02
Class A common stock | Class A Common Stock Equals or Exceeds, $18.00
Property, Plant and Equipment [Line Items]
Minimum threshold price of common stock specified to send notice of redemption to the warrant holders (in dollars per share) | $ / shares						$ 594
Minimum number of trading days | d						20
Consecutive trading day threshold | d						30
Class A common stock | Class A Common Stock Equals or Exceeds, $10.00
Property, Plant and Equipment [Line Items]
Target share price of warrants or rights for redemption (in dollars per share) | $ / shares						$ 330				$ 330
Redemption price per warrant (in dollars per share) | $ / shares						$ 3.30
Number of days for written notice of redemption | d						30
Public Warrants
Property, Plant and Equipment [Line Items]
Purchase of warrants (in shares) | shares												447,222		447,223
Private Placement Warrants
Property, Plant and Equipment [Line Items]
Purchase of warrants (in shares) | shares														219,293
Legacy GeneDx
Property, Plant and Equipment [Line Items]
Restricted cash						$ 12,100				$ 12,100
Business combination, contingent consideration arrangements						150,000		$ 150,000		150,000	150,000
Business combination contingent consideration milestone payment for first year											112,500
Business combination contingent consideration liability period 1						163,000					163,000
Business combination contingent consideration milestone payment for second year						37,500
Business combination contingent consideration liability period 2						$ 219,000
Business combination contingent consideration first milestone percentage						80%
Business combination contingent consideration revenue target of milestone event						100%
Business combination contingent consideration percentage of milestone payment based on revenue target						100%
Earn-out contingent liability						$ 11,000				11,000
Legacy GeneDx | Subsequent Event
Property, Plant and Equipment [Line Items]
Number of shares issuable (in shares) | shares					701,460
Business combination contingent consideration milestone payment for first year					$ 112,500
Legacy GeneDx | Contingent Consideration, Milestone One
Property, Plant and Equipment [Line Items]
Business combination, contingent consideration arrangements						112,500		112,500		112,500	112,500
Legacy GeneDx | Contingent Consideration, Milestone Two
Property, Plant and Equipment [Line Items]
Business combination, contingent consideration arrangements						37,500		$ 37,500		37,500	$ 37,500
Earn-out contingent liability						$ 2,600				$ 2,600
Legacy GeneDx | Minimum
Property, Plant and Equipment [Line Items]
Business combination contingent consideration revenue target of milestone event						90%
Legacy GeneDx | Class A common stock
Property, Plant and Equipment [Line Items]
Price per shares (in dollars per share) | $ / shares			$ 70.95			$ 160.38				$ 160.38
Number of shares issuable (in shares) | shares			2,400,000
Public per share (in dollars per share) | $ / shares			$ 160.38
Sema4 OpCo, Inc
Property, Plant and Equipment [Line Items]
Number of shares issuable (in shares) | shares						576,412
Earn-out contingent liability						$ 0				$ 0
Sema4 OpCo, Inc | Restricted Stock Units (RSUs)
Property, Plant and Equipment [Line Items]
Restricted stock units granted (in shares) | shares				81,819
Total stock-based compensation expense									$ 800
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Triggering Event I
Property, Plant and Equipment [Line Items]
Public per share (in dollars per share) | $ / shares				$ 429
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Triggering Event II
Property, Plant and Equipment [Line Items]
Minimum number of trading days | d				20
Consecutive trading day threshold | d				30
Public per share (in dollars per share) | $ / shares				$ 495
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Triggering Event III
Property, Plant and Equipment [Line Items]
Public per share (in dollars per share) | $ / shares				$ 594
OPKO
Property, Plant and Equipment [Line Items]
Restricted cash						$ 1,300				$ 1,300
OPKO | Class A common stock | Contingent Consideration, Milestone One | Subsequent Event
Property, Plant and Equipment [Line Items]
Number of shares issuable (in shares) | shares		701,460
OPKO | Class A common stock | Contingent Consideration, Milestone Two | Subsequent Event
Property, Plant and Equipment [Line Items]
Number of shares issuable (in shares) | shares		233,820
If election is made | Legacy GeneDx | Class A common stock
Property, Plant and Equipment [Line Items]
Price per shares (in dollars per share) | $ / shares			$ 160.38
If election is made | Legacy GeneDx | Class A common stock | Maximum
Property, Plant and Equipment [Line Items]
Number of shares issuable (in shares) | shares			935,280
Purchases | Supplier Concentration Risk | Supplier A
Property, Plant and Equipment [Line Items]
Concentration risk, percentage						14%	13%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue | Payor A
Concentration Risk [Line Items]
Concentration risk, percentage		24%
Revenue | Payor B
Concentration Risk [Line Items]
Concentration risk, percentage	15%
Revenue | Payor D
Concentration Risk [Line Items]
Concentration risk, percentage		10%
Revenue | Payor E
Concentration Risk [Line Items]
Concentration risk, percentage	24%
Accounts Receivable | Payor B
Concentration Risk [Line Items]
Concentration risk, percentage			14%
Accounts Receivable | Payor E
Concentration Risk [Line Items]
Concentration risk, percentage	15%		14%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 201,895	$ 123,933
Restricted cash	13,044	14,370
Total	$ 214,939	$ 138,303	$ 315,902	$ 401,469

Business Combinations - Narrati

Business Combinations - Narrative (Details)					1 Months Ended
	Apr. 14, 2023 shares	Apr. 29, 2022 USD ($) $ / shares shares	Jul. 22, 2021 USD ($) $ / shares shares	Feb. 09, 2021 USD ($) $ / shares shares	Apr. 30, 2023 shares	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Restricted cash							$ 13,044,000	$ 14,370,000
Class A Common Stock | Private Placement
Business Acquisition [Line Items]
Sale of stock (in shares) | shares		1,515,152
Private placement financing to sell		$ 200,000,000
CMLS Holdings LLC
Business Acquisition [Line Items]
Business combination and net cash received			$ 510,000,000
Number of shares issuable (in shares) | shares				1,060,607
Price per shares (in dollars per share) | $ / shares				$ 330
Number of shares public offering				$ 350,000,000
Number of shares issued and outstanding (in shares) | shares			7,278,498
Transactions costs									$ 51,800,000
CMLS Holdings LLC | Prepaid Expenses and Other Current Assets
Business Acquisition [Line Items]
Transactions costs									$ 9,000,000
CMLS Holdings LLC | Class A Common Stock
Business Acquisition [Line Items]
Number of shares issuable (in shares) | shares			309
Price per shares (in dollars per share) | $ / shares			$ 330
Number of shares public offering			$ 101,880
CMLS Holdings LLC | Common Class B
Business Acquisition [Line Items]
Number of shares issuable (in shares) | shares			5,404,131
Share conversion ratio			0.01
Legacy Sema4 shareholder payout			$ 230,700,000
Legacy GeneDx
Business Acquisition [Line Items]
Payments to acquire businesses, gross		$ 150,000,000
Restricted cash							12,100,000
Business combination, contingent consideration arrangements							150,000,000	150,000,000
Legacy GeneDx | Forecast
Business Acquisition [Line Items]
Business combination, contingent consideration arrangements						$ 37,500,000
Legacy GeneDx | Subsequent Event
Business Acquisition [Line Items]
Number of shares issuable (in shares) | shares					701,460
Legacy GeneDx | Contingent Consideration, Milestone One
Business Acquisition [Line Items]
Business combination, contingent consideration arrangements							$ 112,500,000	$ 112,500,000
Legacy GeneDx | Class A Common Stock
Business Acquisition [Line Items]
Number of shares issuable (in shares) | shares		2,400,000
Price per shares (in dollars per share) | $ / shares		$ 70.95					$ 160.38
Business acquisition issued value assigned		$ 172,000,000
Public per share (in dollars per share) | $ / shares		$ 160.38
OPKO
Business Acquisition [Line Items]
Restricted cash							$ 1,300,000
OPKO | Class A Common Stock | Contingent Consideration, Milestone One | Subsequent Event
Business Acquisition [Line Items]
Number of shares issuable (in shares) | shares	701,460

Business Combinations - Schedul

Business Combinations - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - Legacy GeneDx $ in Thousands	Apr. 29, 2022 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Cash and cash equivalents	$ 0
Accounts receivables	21,651
Inventory	6,210
Prepaid expenses	4,671
Other current assets	320
Property and equipment	29,509
Other non-current assets	6,464
Accounts payable and accrued expenses	(12,862)
Other current liabilities	(15,781)
Deferred tax liabilities	(51,779)
Long-term lease liabilities	(5,798)
Fair value of net assets acquired	178,605
Goodwill	185,871
Aggregate purchase price	364,476
Tradenames and trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Business combination, finite-lived intangibles	50,000
Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Business combination, finite-lived intangibles	48,000
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Business combination, finite-lived intangibles	$ 98,000

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total	$ 43,139	$ 53,941
Diagnostic test revenue
Disaggregation of Revenue [Line Items]
Total	41,850	52,495
Patients with third-party insurance
Disaggregation of Revenue [Line Items]
Total	25,329	47,462
Institutional customers
Disaggregation of Revenue [Line Items]
Total	16,060	4,031
Self-pay patients
Disaggregation of Revenue [Line Items]
Total	461	1,002
Other revenue
Disaggregation of Revenue [Line Items]
Total	$ 1,289	$ 1,446

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Dec. 30, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Loss Contingencies [Line Items]
Adjustment to revenue		$ 2.7	$ 3.6
Deferred costs to fulfill contracts		0.1		$ 0.3
Amortization of deferred costs		0.6	$ 0.3
Certain Payor Matters
Loss Contingencies [Line Items]
Total settlement amount	$ 42
Settlement period	4 years
Settlement amount, first installment payment	$ 15
Settlement amount, next installment payment	$ 5
Liability reserve, potential recoupments, current		$ 37.9
Liability reserve, potential recoupments, noncurrent				$ 39

Revenue Recognition - Remaining

Revenue Recognition - Remaining Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 $ in Millions	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue under existing collaboration service agreements	$ 6
Revenue under existing collaboration service agreements, period for recognition	2 years 3 months 18 days

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended			12 Months Ended
	Apr. 14, 2023 shares	Apr. 29, 2022 $ / shares shares	Apr. 30, 2023 USD ($) shares	Mar. 31, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, net of current portion				$ 6,250			$ 6,250
Cash and cash equivalents				201,895			123,933
Gain (loss) in fair value of warrant and contingent liabilities				0		$ 6,800
Earn-out contingent liability				0			0
Current portion of the contingent consideration liabilities				$ 8,449			$ 6,019
Measurement Input, Revenue Multiple
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input				0.18
Stock price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input | $ / shares				12.21			8.58
Legacy GeneDx
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) in fair value of warrant and contingent liabilities				$ (3,500)	$ (3,400)
Business combination, contingent consideration arrangements				150,000			$ 150,000
Earn-out contingent liability				11,000
Business combination contingent consideration milestone payment for first year							112,500
Business combination contingent consideration liability period 1				163,000			163,000
Business combination contingent consideration milestone payment for second year				37,500
Business combination contingent consideration liability period 2				$ 219,000
Business combination contingent consideration first milestone percentage				80%
Business combination contingent consideration revenue target of milestone event				100%
Business combination contingent consideration percentage of milestone payment based on revenue target				100%
Current portion of the contingent consideration liabilities				$ 8,400
Legacy GeneDx | Contingent Consideration, Milestone One
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration arrangements				112,500			112,500
Legacy GeneDx | Contingent Consideration, Milestone Two
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration arrangements				37,500			$ 37,500
Earn-out contingent liability				$ 2,600
Legacy GeneDx | Subsequent Event
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination contingent consideration milestone payment for first year			$ 112,500
Number of shares issuable (in shares) | shares			701,460
Legacy GeneDx | Class A common stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of shares issuable (in shares) | shares		2,400,000
Price per shares (in dollars per share) | $ / shares		$ 70.95		$ 160.38
Legacy GeneDx | Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination contingent consideration revenue target of milestone event				90%
OPKO | Class A common stock | Subsequent Event | Contingent Consideration, Milestone One
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of shares issuable (in shares) | shares	701,460
OPKO | Class A common stock | Subsequent Event | Contingent Consideration, Milestone Two
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of shares issuable (in shares) | shares	233,820
DECD loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, net of current portion				$ 6,300
Level 2 | DECD loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value				5,100
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds				$ 45,100

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financial Liabilities:
Earn-out contingent liability	$ 0	$ 0
Money market funds | Level 1
Financial Assets:
Money market funds	45,100
Fair Value, Recurring
Financial Assets:
Total financial assets	45,069	16,901
Financial Liabilities:
Total financial liabilities	16,599	12,941
Fair Value, Recurring | DECD loan
Financial Liabilities:
DECD loan	5,110	4,904
Fair Value, Recurring | Contingent consideration based on milestone achievement
Financial Liabilities:
Earn-out contingent liability	11,049	7,619
Fair Value, Recurring | Public warrant liability
Financial Liabilities:
Warrant liability	295	280
Fair Value, Recurring | Private warrant liability
Financial Liabilities:
Warrant liability	145	138
Fair Value, Recurring | Level 1
Financial Assets:
Total financial assets	45,069	16,901
Financial Liabilities:
Total financial liabilities	295	280
Fair Value, Recurring | Level 1 | DECD loan
Financial Liabilities:
DECD loan	0	0
Fair Value, Recurring | Level 1 | Contingent consideration based on milestone achievement
Financial Liabilities:
Earn-out contingent liability	0	0
Fair Value, Recurring | Level 1 | Public warrant liability
Financial Liabilities:
Warrant liability	295	280
Fair Value, Recurring | Level 1 | Private warrant liability
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Level 2
Financial Assets:
Total financial assets	0	0
Financial Liabilities:
Total financial liabilities	5,255	5,042
Fair Value, Recurring | Level 2 | DECD loan
Financial Liabilities:
DECD loan	5,110	4,904
Fair Value, Recurring | Level 2 | Contingent consideration based on milestone achievement
Financial Liabilities:
Earn-out contingent liability	0	0
Fair Value, Recurring | Level 2 | Public warrant liability
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Level 2 | Private warrant liability
Financial Liabilities:
Warrant liability	145	138
Fair Value, Recurring | Level 3
Financial Assets:
Total financial assets	0	0
Financial Liabilities:
Total financial liabilities	11,049	7,619
Fair Value, Recurring | Level 3 | DECD loan
Financial Liabilities:
DECD loan	0	0
Fair Value, Recurring | Level 3 | Contingent consideration based on milestone achievement
Financial Liabilities:
Earn-out contingent liability	11,049	7,619
Fair Value, Recurring | Level 3 | Public warrant liability
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Level 3 | Private warrant liability
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Money market funds
Financial Assets:
Money market funds	45,069	16,901
Fair Value, Recurring | Money market funds | Level 1
Financial Assets:
Money market funds	45,069	16,901
Fair Value, Recurring | Money market funds | Level 2
Financial Assets:
Money market funds	0	0
Fair Value, Recurring | Money market funds | Level 3
Financial Assets:
Money market funds	$ 0	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Utilized in Determining Valuation (Details)	Mar. 31, 2023 $ / shares yr	Dec. 31, 2022 yr $ / shares
Stock price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input | $ / shares	12.21	8.58
Expected volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	1.200	1.075
Expected term (in years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input | yr	300	600
Risk-free interest rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.0487	0.0476

Property and Equipment - Compon

Property and Equipment - Components (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 156,039	$ 152,987
Less: accumulated depreciation and amortization	(106,531)	(101,460)
Property and equipment, net	49,508	51,527
Laboratory equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	42,370	41,255
Equipment under finance leases
Property, Plant and Equipment [Line Items]
Total property and equipment	21,384	21,384
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	35,560	35,561
Capitalized software
Property, Plant and Equipment [Line Items]
Total property and equipment	32,171	32,171
Building under finance lease
Property, Plant and Equipment [Line Items]
Total property and equipment	8,059	6,276
Construction in-progress
Property, Plant and Equipment [Line Items]
Total property and equipment	3,533	3,386
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	9,185	9,177
Furniture, fixtures and other equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 3,777	$ 3,777

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 5,130	$ 5,803
Software amortization expense	1,000	$ 1,600
Impairment loss	1,600
Building
Property, Plant and Equipment [Line Items]
Finance lease, impairment loss	$ 800

Property and Equipment - Deprec

Property and Equipment - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	$ 5,130	$ 5,803
Cost of services
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	589	2,816
Research and development
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	852	1,849
Selling and marketing
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	2	1
General and administrative
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	$ 3,687	$ 1,137

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2019	Jun. 01, 2017
Related Party Transaction [Line Items]
Related party revenue	$ 700	$ 0
Commitment to receive future capital contributions					$ 55,000
Cumulative funding drawn				$ 55,000
Due to related parties	4,315		$ 3,593
Transition Services Agreement | OPKO
Related Party Transaction [Line Items]
Related party costs	800
Due to related parties	600		400
Receivables related to acquisition closing working capital adjustment			1,300
Affiliated Entities
Related Party Transaction [Line Items]
Related party costs	2,562	2,340
Affiliated Entities | Cost of services
Related Party Transaction [Line Items]
Related party costs	815	1,056
Affiliated Entities | Service Agreements
Related Party Transaction [Line Items]
Related party costs	1,900	$ 1,900
Due to related parties	3,100		2,400
Affiliated Entities | Purchase Of Diagnostic Testing Kits And Materials
Related Party Transaction [Line Items]
Purchases from related party	500
Payables	400		$ 400
Affiliated Entities | Purchase Of Diagnostic Testing Kits And Materials | Cost of services
Related Party Transaction [Line Items]
Purchases from related party	$ 100

Related Party Transactions - Re

Related Party Transactions - Related Party Expenses (Details) - Affiliated Entities - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Related Party Transaction [Line Items]
Total related party costs	$ 2,562	$ 2,340
Cost of services
Related Party Transaction [Line Items]
Total related party costs	815	1,056
Related party expenses
Related Party Transaction [Line Items]
Total related party costs	$ 1,747	$ 1,284

Long-Term Debt - Loan and Secur

Long-Term Debt - Loan and Security Agreement (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Nov. 15, 2021 USD ($)
Debt Instrument [Line Items]
Total	$ 39,629,000		$ 49,705,000
SVB Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility				$ 125,000,000
Interest rate				4%
Payments of debt issuance costs		$ 500,000
Debt instrument, debt issuance costs, each anniversary	500,000
Total	$ 1,000,000
Existing issued and outstanding	65%
Line of credit facility borrowing capacity	$ 135,000,000
Number of borrowers	1.25
Trailing period for minimum revenue targets	6 months
Outstanding borrower	$ 50,000,000
Long-term line of credit	$ 0
SVB Agreement | Letter of Credit
Debt Instrument [Line Items]
Revolving credit facility				$ 20,000,000

Long-Term Debt - 2016 Funding C

Long-Term Debt - 2016 Funding Commitment (Details) $ in Thousands	1 Months Ended		3 Months Ended
	Jan. 31, 2023 USD ($) milestone	Jun. 30, 2017 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Debt Instrument [Line Items]
Long-term debt principal payments			$ 2,000	$ 0
DECD Loan Agreement
Debt Instrument [Line Items]
Total funding commitment		$ 15,500
Interest rate	2%	2%
Administrative expenses over period		10 years
Maximum loan forgiveness			12,300
Debt forgiven			4,500
Number of forgiveness milestones | milestone	2
Outstanding loan balance			$ 6,300
DECD Loan Agreement, Phase 2 Funding
Debt Instrument [Line Items]
Debt forgiven	$ 2,750
Long-term debt principal payments	2,000
DECD Loan Agreement, Phase 3 Funding
Debt Instrument [Line Items]
Debt forgiveness eligible	2,000
DECD Loan Agreement, Final Phase Funding
Debt Instrument [Line Items]
Debt forgiveness eligible	$ 1,000

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
2023 (remainder of year)	$ 0
2024	497
2025	1,211
2026	1,234
2027	1,260
Thereafter	2,048
Total maturities of long-term debt	6,250
Less: current portion of long-term debt	0	$ (4,750)
Total long-term debt, net of current maturities	$ 6,250	$ 6,250

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2019 period	Mar. 31, 2023 USD ($)	Feb. 28, 2023	Dec. 31, 2022 USD ($)	Jul. 31, 2022	Apr. 30, 2022	Jan. 31, 2020
Lessee, Lease, Description [Line Items]
Letter of credit		$ 0.9		$ 0.9
Operating lease, remaining term		13 years	23 years			9 years
Payment for early termination fees		$ 8.4
Increase in operating lease liability		2
Increase in financing lease liability		2.6
Impairment loss		$ 1.6
Finance lease, interest rate (percent)		13.10%
Finance lease, interest rate modified (percent)		8.50%
Building
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract	325 months						10 years
Lease term					13 months
Lease cancellation period	196 months
Land to total value, percentage	25%
Finance lease, impairment loss		$ 0.8
One Renewal Period | Building
Lessee, Lease, Description [Line Items]
Number of capital lease renewal terms | period	1
Lease term	10 years
Two Renewal Periods | Building
Lessee, Lease, Description [Line Items]
Number of capital lease renewal terms | period	2
Lease term	5 years

Leases - Schedule of Assets and

Leases - Schedule of Assets and Liabilities, Lessee (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Operating lease assets	$ 33,235	$ 32,758
Finance lease assets	$ 9,668	8,604
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net
Total lease assets	$ 42,903	41,362
Liabilities
Operating	2,349	2,409
Finance	2,850	3,712
Non-current
Operating	$ 45,816	44,468
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term lease liabilities
Finance	$ 18,067	15,545
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term lease liabilities
Total liabilities	$ 69,082	$ 66,134
Short-term lease liabilities
Liabilities
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Short-term lease liabilities
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Short-term lease liabilities

Leases - Schedule of Lease, Cos

Leases - Schedule of Lease, Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating lease cost
Operating lease cost	$ 1,735	$ 1,380
Short-term lease cost	203	169
Variable lease cost	264	127
Total operating lease cost	2,202	1,676
Finance lease cost
Depreciation and amortization of leased assets	775	912
Interest on lease liabilities	544	552
Total finance lease cost	1,319	1,464
Total lease cost	$ 3,521	$ 3,140

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Rental Payments for Leases (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Operating leases
2023 (remainder of the year)	$ 3,005
2024	5,529
2025	5,960
2026	6,110
2027	6,259
Thereafter	43,794
Total	70,657
Less: imputed interest	(22,492)
Present value of lease liabilities	48,165
Finance leases
2023 (remainder of the year)	760
2024	4,117
2025	2,511
2026	2,031
2027	2,045
Thereafter	25,135
Total	36,599
Less: imputed interest	(15,682)
Present value of lease liabilities	20,917
Total
2023 (remainder of the year)	3,765
2024	9,646
2025	8,471
2026	8,141
2027	8,304
Thereafter	68,929
Total	107,256
Less: imputed interest	(38,174)
Present value of lease liabilities	$ 69,082

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Information Related to Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Weighted-average remaining lease term (years)
Operating leases (in years)	10 years 8 months 12 days
Finance leases (in years)	11 years 6 months
Weighted-average discount rate
Operating leases (as percent)	6.30%
Finance leases (as percent)	10.80%
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 346
Operating cash flows from finance leases	146
Financing cash flows from finance lease	$ 1,046

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase commitment, remaining minimum amount committed	$ 3.4

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details)			3 Months Ended
	Apr. 14, 2023 shares	Jul. 22, 2021 shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) employee shares	Mar. 31, 2023 USD ($) consultant shares	Mar. 31, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense | $					$ 48,000					$ 17,559,000
Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares) | shares				0
Triggering Event I
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in dollars per share) | $ / shares							$ 60.06
Restricted stock units forfeited (in dollars per share) | $ / shares							0
Triggering Event II
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in dollars per share) | $ / shares							45.87
Restricted stock units forfeited (in dollars per share) | $ / shares							0
Triggering Event III
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in dollars per share) | $ / shares							31.02
Restricted stock units forfeited (in dollars per share) | $ / shares							$ 0
2017 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value re-measurement period for the liability awards			6 months
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted | shares		0
Weighted average remaining contractual life (years), options exercisable		10 years
Vesting period		4 years
Number of share issuance (in shares) | shares		991,970
2021 Plan | Subsequent Event | Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares) | shares	787,879
2021 Employee Stock Purchase Plan | Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share issuance (in shares) | shares			336,816	336,816	336,816	336,816	336,816	336,816	336,816
Number of shares equal to percent						1%
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation cost on the unvested stock options | $			$ 8,800,000	$ 8,800,000	$ 8,800,000	$ 8,800,000	$ 8,800,000	$ 8,800,000	$ 8,800,000
Weighted-average vesting period for compensation cost			1 year 8 months 12 days
Options to purchase common stock | 2017 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted | shares				0
Weighted average remaining contractual life (years), options exercisable			10 years
Vesting period			4 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Stock conversion ratio			1	1	1	1	1	1	1
Restricted stock units granted (in shares) | shares				560,725
Restricted stock units granted (in dollars per share) | $ / shares							$ 10.78
Restricted stock units forfeited (in dollars per share) | $ / shares							$ 138.91
Restricted Stock Units (RSUs) | Board of Directors Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in shares) | shares				18,794
Restricted Stock Units (RSUs) | Triggering Event I
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting commencement date			12 months
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, expense, reversal | $					$ 8,100,000
Number of shares granted (in shares)								1	1
Total stock-based compensation expense | $					3,800,000
Outstanding vested value | $			$ 0	$ 0	0	$ 0	$ 0	$ 0	$ 0
Earn Out RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, expense, reversal | $					$ 800,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Class A Common Stock	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Stock Options Outstanding
Beginning balance (in shares) | shares	798,873
Options granted (in shares) | shares	0
Options exercised (in shares) | shares	(50,444)
Options forfeited and cancelled (in shares) | shares	(38,829)
Ending balance (in shares) | shares	709,600
Options outstanding, exercisable at end of period (in shares) | shares	395,403
Weighted Average Exercise Price
Weighted-average exercise price (in dollars per share) | $ / shares	$ 49.83
Weighted average exercise price, options granted (in dollars per share) | $ / shares	0
Weighted average exercise price, options exercised (in dollars per share) | $ / shares	5.05
Weighted average exercise price, options forfeited and cancelled (in dollars per share) | $ / shares	66.12
Weighted-average exercise price (in dollars per share) | $ / shares	52.09
Weighted average exercise price, options exercisable (in dollars per share) | $ / shares	$ 38.04

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Assumptions (Details) - Options to purchase common stock	3 Months Ended
	Mar. 31, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 5 months 23 days
Risk-free interest rate	1.65%
Fair value of Class A common stock (in dollars per share)	$ 108.57
Expected volatility	65.20%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 21 days
Risk-free interest rate	1.70%
Fair value of Class A common stock (in dollars per share)	$ 113.85
Expected volatility	67.60%

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted Stock Units Outstanding
Restricted Stock Units Outstanding (in shares) | shares	855,061
Restricted Stock Units Granted (in shares) | shares	560,725
Restricted Stock Units Vested (in shares) | shares	(54,175)
Restricted Stock Units Forfeited (in shares) | shares	(97,621)
Restricted Stock Units Outstanding (in shares) | shares	1,263,990
Weighted Average Grant Date Fair Value Per Unit
Weighted Average Grant Date Fair Value Per Unit (in dollar per share) | $ / shares	$ 77.88
Restricted Stock Units Granted (in dollars per share) | $ / shares	10.78
Restricted Stock Units Vested (in dollars per share) | $ / shares	102.45
Restricted Stock Units Forfeited (in dollars per share) | $ / shares	138.91
Weighted Average Grant Date Fair Value Per Unit (in us dollar per share) | $ / shares	$ 41.56

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 48	$ 17,559
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	(1,666)	1,381
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	943	4,341
Selling and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	63	2,825
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 708	$ 9,012

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax benefit	$ 147	$ 0
Effective tax rate	0.30%

Net Income (loss) per Share - B

Net Income (loss) per Share - Basic and Diluted (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares
Numerator:
Net (loss) income attributable to common stockholders | $	$ (60,989)	$ (76,896)
Denominator:
Denominator for basic earnings per share-weighted-average common shares (in shares) | shares	20,061,945	7,405,113
Denominator for diluted earnings per share-weighted-average common shares (in shares) | shares	20,061,945	7,405,113
Basic earnings (loss) income per share (in dollars per share) | $ / shares	$ (3.04)	$ (10.38)
Diluted earnings (loss) income per share (in dollars per share) | $ / shares	$ (3.04)	$ (10.38)
Reverse stock split, conversion ratio	0.03

Net Income (loss) per Share - P

Net Income (loss) per Share - Potentially Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,216,517	2,485,717
Outstanding options and RSUs to purchase Class A common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,973,590	1,242,790
Outstanding warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	666,515	666,515
Outstanding earn-out shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	554,799	503,367
Outstanding earn-out RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	21,613	73,045

Restructuring Costs (Details)

Restructuring Costs (Details) $ in Thousands		3 Months Ended
	Nov. 14, 2022 position	Mar. 31, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring cost number of positions eliminated | position	500
Number of positions eliminated, expected percent		32.50%
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		$ 5,023
Charged to Costs and Expenses		326
Payments and Other		(3,954)
Restructuring reserve, ending balance		1,395
Severance
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		4,770
Charged to Costs and Expenses		308
Payments and Other		(3,700)
Restructuring reserve, ending balance		1,378
Others
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		253
Charged to Costs and Expenses		18
Payments and Other		(254)
Restructuring reserve, ending balance		$ 17

Supplemental Financial Inform_3

Supplemental Financial Information - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Accounts payable	$ 36,918	$ 46,017
Accrued purchases	27,570	20,314
Reserves for refunds to insurance carriers	5,000	17,001
Other	401	1,546
Total	$ 69,889	$ 84,878

Supplemental Financial Inform_4

Supplemental Financial Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Accrued bonus	$ 3,571	$ 8,429
Accrued payroll	754	3,905
Accrued benefits	4,104	1,529
Accrued commissions	958	1,656
Accrued severance	1,378	4,770
Current portion of long-term debt	0	4,750
Indemnification liabilities	12,144	13,470
Current portion of the contingent consideration liabilities	8,449	6,019
Other	8,271	5,177
Total	$ 39,629	$ 49,705

Segment Reporting - Narrative (

Segment Reporting - Narrative (Details) - segment	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Segment Reporting [Abstract]
Number of reportable segments	2	2	1

Segment Reporting - Schedule of

Segment Reporting - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 43,139	$ 53,941
Depreciation and amortization	5,130	5,803
Stock-based compensation	48	17,559
Expense of management	326
Gross margin (loss)	15,236	5,625
Diagnostic test revenue:
Segment Reporting Information [Line Items]
Revenue	41,850	52,495
Patients with third-party insurance
Segment Reporting Information [Line Items]
Revenue	25,329	47,462
Institutional customers
Segment Reporting Information [Line Items]
Revenue	16,060	4,031
Self-pay patients
Segment Reporting Information [Line Items]
Revenue	461	1,002
Other revenue
Segment Reporting Information [Line Items]
Revenue	1,289	$ 1,446
Operating Segments
Segment Reporting Information [Line Items]
Revenue	43,139
Adjusted cost of services	28,906
Adjusted gross margin (loss)	14,233
Depreciation and amortization	589
Stock-based compensation	(1,666)
Expense of management	74
Gross margin (loss)	15,236
Legacy GeneDx
Segment Reporting Information [Line Items]
Revenue	40,693
Legacy GeneDx | Diagnostic test revenue:
Segment Reporting Information [Line Items]
Revenue	39,404
Legacy GeneDx | Patients with third-party insurance
Segment Reporting Information [Line Items]
Revenue	22,878
Legacy GeneDx | Institutional customers
Segment Reporting Information [Line Items]
Revenue	16,060
Legacy GeneDx | Self-pay patients
Segment Reporting Information [Line Items]
Revenue	466
Legacy GeneDx | Other revenue
Segment Reporting Information [Line Items]
Revenue	1,289
Legacy GeneDx | Operating Segments
Segment Reporting Information [Line Items]
Revenue	40,693
Adjusted cost of services	26,826
Adjusted gross margin (loss)	13,867
Depreciation and amortization	476
Stock-based compensation	305
Expense of management	43
Gross margin (loss)	13,043
Legacy Sema4
Segment Reporting Information [Line Items]
Revenue	2,446
Legacy Sema4 | Diagnostic test revenue:
Segment Reporting Information [Line Items]
Revenue	2,446
Legacy Sema4 | Patients with third-party insurance
Segment Reporting Information [Line Items]
Revenue	2,451
Legacy Sema4 | Institutional customers
Segment Reporting Information [Line Items]
Revenue	0
Legacy Sema4 | Self-pay patients
Segment Reporting Information [Line Items]
Revenue	(5)
Legacy Sema4 | Other revenue
Segment Reporting Information [Line Items]
Revenue	0
Legacy Sema4 | Operating Segments
Segment Reporting Information [Line Items]
Revenue	2,446
Adjusted cost of services	2,080
Adjusted gross margin (loss)	366
Depreciation and amortization	113
Stock-based compensation	(1,971)
Expense of management	31
Gross margin (loss)	$ 2,193

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Apr. 30, 2022
GeneDx
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 0	$ 0	$ 185,900
Trade Names, Trademarks And Developed Technology
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	2,300
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 1,200

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - GeneDx $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 0
Additions	0
Measurement period adjustments	478
Impairment charges	(478)
Goodwill, ending balance	$ 0

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Acquired Intangible Assets (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 196,000
Accumulated Amortization	12,856
Net Carrying Value	183,144
Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	50,000
Accumulated Amortization	2,864
Net Carrying Value	$ 47,136
Weighted-Average Amortization Period (in years)	15 years 1 month 6 days
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 48,000
Accumulated Amortization	5,500
Net Carrying Value	$ 42,500
Weighted-Average Amortization Period (in years)	7 years 1 month 6 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 98,000
Accumulated Amortization	4,492
Net Carrying Value	$ 93,508
Weighted-Average Amortization Period (in years)	19 years 1 month 6 days

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remainder of the year)	$ 10,519
2024	14,025
2025	14,025
2026	14,025
2027	14,025
Thereafter	116,525
Net Carrying Value	$ 183,144

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Millions				3 Months Ended
	May 04, 2023 $ / shares	Apr. 17, 2023 USD ($) shares	Apr. 14, 2023 shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Subsequent Event [Line Items]
Common stock par value (in dollars per share)				$ 0.0001	$ 0.0001
Reverse stock split, conversion ratio				0.03
Class A common stock
Subsequent Event [Line Items]
Common stock par value (in dollars per share)				$ 0.0001
Class A common stock | Minimum
Subsequent Event [Line Items]
Reverse stock split, conversion ratio				0.10
Class A common stock | Maximum
Subsequent Event [Line Items]
Reverse stock split, conversion ratio				0.02
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split, conversion ratio	0.030
Subsequent Event | Class A common stock
Subsequent Event [Line Items]
Common stock par value (in dollars per share)	$ 0.0001
Subsequent Event | Class A common stock | Direct Offering
Subsequent Event [Line Items]
Sale of stock (in shares) | shares		676,868
Net proceeds | $		$ 7.6
Subsequent Event | OPKO | Class A common stock | Contingent Consideration, Milestone One
Subsequent Event [Line Items]
Number of shares issuable (in shares) | shares			701,460